<SEC-DOCUMENT>0001213900-24-032578.txt : 20240412
<SEC-HEADER>0001213900-24-032578.hdr.sgml : 20240412
<ACCEPTANCE-DATETIME>20240412163023
ACCESSION NUMBER:		0001213900-24-032578
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240412
DATE AS OF CHANGE:		20240412

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269306
		FILM NUMBER:		24841876

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea0203721-424b5_neurosense.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-269306</B></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To the Prospectus dated January 30, 2023)</B></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,732,000 Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pre-Funded Warrants to Purchase up to 1,248,000
Ordinary Shares</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering on a &ldquo;reasonable best efforts&rdquo;
basis 1,732,000 ordinary shares, no par value, or the Ordinary Shares. The purchase price of each Ordinary Share is $1.50. We are also
offering on a &ldquo;reasonable best efforts&rdquo; basis pre-funded warrants to purchase up to 1,248,000 Ordinary Shares to the purchaser,
whose purchase of additional Ordinary Shares in this offering would otherwise result in such purchaser, together with its affiliates
and certain related parties, beneficially owning more than 9.99% of our outstanding share capital immediately following the consummation
of this offering and assuming the exercise of such warrants, or the Pre-Funded Warrants. The purchase price of each Pre-Funded Warrant
is equal to $1.4999 (which is equal to the sale price of the Ordinary Shares minus $0.0001, the exercise price of each Pre-Funded Warrant).
The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised
in full. This offering also relates to the Ordinary Shares issuable upon exercise of the Pre-Funded Warrants sold in this offering.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a concurrent private placement, we are also
selling to the purchaser of our Ordinary Shares and Pre-Funded Warrants in this offering, ordinary warrants to purchase 2,980,000 Ordinary
Shares, or the Ordinary Warrants. The Ordinary Warrants will be exercisable immediately upon issuance at an exercise price of $1.50 per
Ordinary Share and will expire on the fifth anniversary of the original issuance date. The Ordinary Warrants and the Ordinary Shares
issuable upon exercise of the Ordinary Warrants are not being registered under the Securities Act of 1933, as amended, or the Securities
Act, and are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant
to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities are being sold in this offering
to the purchaser under a securities purchase agreement between us and such purchaser, dated April 10, 2024.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Ordinary Shares and publicly-listed warrants,
each warrant exercisable for one Ordinary Share, are traded on the Nasdaq Capital Market, or Nasdaq, under the symbols &ldquo;NRSN&rdquo;
and &ldquo;NRSNW,&rdquo; respectively. The last reported sale price for our Ordinary Shares on April 10, 2024 as quoted on Nasdaq was
$1.66 per share, and the last reported sale price for our warrants on April 10, 2024 as quoted on Nasdaq was $0.2532 per warrant. There
is no established public trading market for the Pre-Funded Warrants and we do not expect a market to develop. In addition, we do not
intend to apply for a listing of the Pre-Funded Warrants on any national securities exchange or other nationally recognized trading system.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The highest aggregate market value of our outstanding
Ordinary Shares held by non-affiliates within the 60 days prior to this prospectus supplement was approximately $8.2 million, based on
15,602,042 Ordinary Shares outstanding, of which 3,993,286 are held by non-affiliates, and the closing sale price of our Ordinary Shares
on Nasdaq of $2.11 on March 4, 2024. Pursuant to General Instruction I.B.5 of Form F-3, in no event will we sell, pursuant to the registration
statement of which this prospectus supplement forms a part, securities with a value exceeding one-third of the aggregate market value
of our outstanding Ordinary Shares held by non-affiliates in any 12 calendar month period, so long as the aggregate market value of our
Ordinary Shares held by non-affiliates is less than $75.0 million. During the 12 calendar-month period that ends on, and includes, the
date of this prospectus supplement, we have sold approximately $2.9 million of our securities pursuant to General Instruction I.B.5 of
Form F-3.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investing
in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-5</B></FONT> &nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>of
this prospectus supplement and the risk factors in the documents incorporated by reference into this prospectus supplement.</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission,
or the SEC, nor any state or other foreign securities commission has approved or disapproved of these securities or determined if this
prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged A.G.P./Alliance Global Partners,
or the Placement Agent, as our exclusive placement agent in connection with this offering. This offering is being conducted on a &ldquo;reasonable
best efforts&rdquo; basis and the Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase
or sale of any specific number or dollar amount of securities but will use their best efforts to sell the securities offered. We have
not agreed to a date on which this offering will end, any minimum purchase requirement or any arrangements to place the funds in an escrow,
trust or similar account. We have agreed to pay the Placement Agent fees set forth in the table below. See &ldquo;Plan of Distribution&rdquo;
beginning on page S-15 of this prospectus supplement for more information.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PER<BR> ORDINARY<BR> SHARE</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PER<BR> PRE-FUNDED<BR> WARRANT</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">TOTAL</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.4999</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,469,875.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent fees<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.104993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">312,891.27</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Proceeds to the Company (before expenses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">1.394907</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,156,983.93</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Placement Agent has agreed to credit us 3.5% of the placement agent
fee and has also agreed to be paid the placement agent fee in the form of a $50,000 fee in cash and to receive 70,964 of our Ordinary
Shares. See
&ldquo;Plan of Distribution&rdquo; beginning on page S-15 of this prospectus supplement for a description of the compensation payable
to the Placement Agent.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery of the securities is expected to be
made on or about April 15, 2024.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole&nbsp;Placement Agent</I></FONT></TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 7pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>A.G.P.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 7pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus Supplement dated April 10, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 90%; padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT
    THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: center">S-ii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY
    NOTE REGARDING FORWARD LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center">S-iii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS&nbsp;
    SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: center">S-1</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
    OFFERING</FONT></A></TD>
    <TD STYLE="text-align: center">S-3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK
    FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center">S-5</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE
    OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center">S-8</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND
    POLICY</FONT></A></TD>
    <TD STYLE="text-align: center">S-9</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION
    OF THE SECURITIES WE ARE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: center">S-10</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRIVATE
    PLACEMENT TRANSACTION</FONT></A></TD>
    <TD STYLE="text-align: center">S-12</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: center">S-13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="text-align: center">S-14</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN
    OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center">S-15</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
    MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center">S-18</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center">S-18</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center">S-18</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EXPENSES</U></FONT></A></TD>
    <TD STYLE="text-align: center">S-19</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><A HREF="#s_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION
    INCORPORATED BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center">S-20</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; text-align: left; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; unicode-bidi: embed"><B>Page</B></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; width: 90%; text-align: left; unicode-bidi: embed"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: center; unicode-bidi: embed">ii</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THE COMPANY</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">1</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">4</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">5</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">6</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAPITALIZATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">7</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER AND LISTING DETAILS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">8</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">9</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF ORDINARY SHARES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">10</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">11</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">12</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SUBSCRIPTION RIGHTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">18</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">19</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: bottom"><A HREF="#a_014">PLAN OF DISTRIBUTION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">20</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: bottom"><A HREF="#a_015">TAXATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">23</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">24</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">24</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">24</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">25</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENFORCEABILITY OF CIVIL LIABILITIES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">26</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPENSES ASSOCIATED WITH THE REGISTRATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">27</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_001"></A>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
and the accompanying prospectus relate to the offering of the securities. You should read this prospectus supplement, the accompanying
prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing
prospectus that we may authorize for use in connection with this offering in their entirety before making an investment decision. You
should also read and consider the information in the documents to which we have referred you in the section of this prospectus supplement
titled &ldquo;Information Incorporated by Reference.&rdquo; These documents contain important information that you should consider when
making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We further note that the
representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated
by reference herein or therein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you.
Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are responsible for the
information contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus and in any free
writing prospectus that we may authorize for use in connection with this offering. We have not, and the Placement Agent has not, authorized
any other person to provide you with different information, and neither we nor the Placement Agent takes any responsibility for any other
information that others may give you. When you make a decision about whether to invest in our securities, you should not rely upon any
information other than the information in this prospectus supplement or the accompanying prospectus, including any free writing prospectus
that we have authorized for use in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should assume that the
information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus
supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this
offering is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and
prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering to sell,
and seeking offers to buy, and the Placement Agent are soliciting offers to buy, securities only in jurisdictions where offers and sales
are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the securities in certain
jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and
the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and
the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement
and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an
offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction
in which it is unlawful for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;NeuroSense Therapeutics&rdquo; refer to NeuroSense Therapeutics
Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reporting currency and
functional currency is the U.S. dollar. All references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; are to United States dollars, the
lawful currency of the United States.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_002"></A>CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement,
the accompanying prospectus and certain information incorporated by reference in this prospectus supplement and the accompanying prospectus
contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act and Section 21E of the U.S.
Securities Exchange Act of 1934, as amended, or the Exchange Act, and other securities laws. Many of the forward-looking statements contained
in this prospectus supplement, the accompanying prospectus and the documents incorporated herein and therein can be identified by the
use of forward-looking words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo;
&ldquo;would&rdquo; and other similar expressions that are predictions of or indicate future events and future trends, although not all
forward-looking statements contain these identifying words.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are based on our management&rsquo;s beliefs and assumptions and on information currently available to our management. Such statements
are subject to substantial risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking
statements due to a variety of factors, including, but not limited to, those identified under the section titled &ldquo;Risk Factors&rdquo;
in this prospectus supplement, the accompanying prospectus or the documents incorporated herein or therein. These risks and uncertainties
include factors relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
going concern reference in our financial statements and our need for substantial additional financing to achieve our goals;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
limited operating history and history of incurring significant losses and negative cash flows since our inception, which we anticipate
will continue for the foreseeable future;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
dependence on the success of our lead product candidate, PrimeC, including our obtaining of regulatory approval to market PrimeC in the
United States;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
limited experience in conducting clinical trials and reliance on clinical research organizations and others to conduct them;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to advance our preclinical product candidates into clinical development and through regulatory approval;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
results of our clinical trials, which may fail to adequately demonstrate the safety and efficacy of our product candidates;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
reliance on third parties in marketing, producing or distributing products and research materials for certain raw materials, compounds
and components necessary to produce PrimeC for clinical trials and to support commercial scale production of PrimeC, if approved;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
receipt of regulatory clarity and approvals for our therapeutic candidates and the timing of such regulatory clarity and approvals and
of other regulatory filings and approvals;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">estimates
of our expenses, revenues, capital requirements and our needs for additional financing;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to maintain the listing of our ordinary shares on Nasdaq;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
impact of the public health, political and security situation in Israel, the U.S. and other countries in which we may obtain approvals
for our products or our business;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
impacts on our ongoing and planned trials and manufacturing as a result of the war in Israel; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">those
factors referred to in our most recent Annual Report on Form 20-F&nbsp;incorporated by reference herein in &ldquo;Item 3. Key Information
&mdash; D. Risk Factors,&rdquo; &ldquo;Item 4. Information on the Company,&rdquo; and &ldquo;Item&nbsp;5. Operating and Financial Review
and Prospects,&rdquo; as well as in our most recent Annual Report on Form 20 generally, which is incorporated by reference into this
prospectus.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preceding list is not
intended to be an exhaustive list of all of our risks and uncertainties. As a result of these factors, we cannot assure you that the
forward-looking statements in this prospectus supplement, the accompanying prospectus or the documents incorporated herein or therein
will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In
light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation
or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, statements that
&ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based
upon information available to us as of the date of this prospectus supplement, accompanying prospectus or any document incorporated herein
or therein, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete,
and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise required
by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any
revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this prospectus
supplement and the accompanying prospectus, the documents incorporated herein and therein, completely and with the understanding that
our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these
cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_003"></A>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary
highlights information contained elsewhere or incorporated by reference into this prospectus supplement and the accompanying
prospectus. This summary does not contain all of the information that you should consider before investing in our securities. You
should carefully read the entire prospectus supplement and the accompanying prospectus, including the &ldquo;Risk Factors&rdquo;
section, starting on page S-5 of this prospectus supplement and in the documents incorporated by reference into this prospectus
supplement and the accompanying prospectus, as well as the financial statements and notes thereto and the other information
incorporated by reference herein and therein, before making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biotechnology
company focused on discovering and developing treatments for people living with neurodegenerative diseases, including Amyotrophic Lateral
Sclerosis, or ALS, Alzheimer&rsquo;s Disease and Parkinson&rsquo;s Disease. We believe these diseases represent some of the most significant
unmet medical needs of our time, with limited effective therapeutic options available. The burden of these diseases on both patients and
society is substantial. For example, the average annual cost of ALS alone is $180,000 per patient, and its estimated annual burden on
the U.S. healthcare system is greater than $1 billion. Due to the complexity of neurodegenerative diseases, our strategy is utilizing
a combined therapeutic approach to target multiple disease-related pathways.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
lead therapeutic candidate, PrimeC, is a novel extended-release oral formulation, fixed-dose combination of two FDA-approved drugs, ciprofloxacin
and celecoxib. PrimeC is designed to treat ALS by modulating microRNA synthesis, iron accumulation, and neuroinflammation, all of which
are hallmarks of ALS pathology. The U.S.&nbsp;Food and Drug Administration, or the FDA and the European Medicines Agency, or the EMA
have granted PrimeC orphan drug designation for the treatment of ALS.&nbsp;In addition, the EMA has granted PrimeC the Small and Medium-Sized
Enterprise, or SME, status, which offers significant potential benefits leading up to and following drug regulatory approval. We believe
PrimeC&rsquo;s multifunctional mechanism of action has the potential to significantly prolong lifespan and improve ALS patients&rsquo;
quality of life, thereby reducing the burden of this debilitating disease on both patients and healthcare systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PrimeC
is currently being evaluated in PARADIGM, a Phase&nbsp;2b randomized, multi-center, multinational, prospective, double-blind, placebo-controlled
study, to evaluate safety, tolerability, and efficacy of PrimeC in 68 people living with ALS.&nbsp;For the six-month phase of the trial
which commenced in May 2022, participants were administered PrimeC or placebo at a 2:1 ratio, respectively. Study participants were allowed
to continue standard of care treatment of approved products. The primary endpoints of the study are an evaluation of ALS-biomarkers as
well as safety and tolerability assessment. Secondary and exploratory endpoints are the evaluation of clinical efficacy (ALS Functional
Rating Scale&nbsp;&mdash;&nbsp;Revised, or ALSFRS-R, and slow vital capacity), survival, and improvement in quality of life. All subjects
who completed the six-month double-blind, placebo-controlled dosing period had the opportunity to be transferred to the PrimeC active
arm for a 12-month open label extension. The study completed enrollment in May&nbsp;2023, enrolling 69 participants, in which 68 are
living with ALS and one participant who was misdiagnosed for ALS and was excluded from the evaluations. Four ALS clinical centers participated
in the study in three territories: Israel, Italy, and Canada. In December 2023, we reported that we met the primary safety and tolerability
endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our six month double-blind phase of PARADIGM.
We also expect to report on an additional primary biomarkers endpoint assessing ALS hallmarks, TDP-43 and Prostagladin2 in the second
or third quarter of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following
the FDA&rsquo;s recommendation for additional non-clinical data to support long term use of Ciprofloxacin (as PrimeC is intended for
long-term administration in treating ALS), we initiated a long-term toxicology study. Results from this study are expected in the third
quarter of 2024 towards the anticipated initiation of Phase 3 study in the US. We plan to hold an end of Phase 2 meeting with the FDA
and EMA in the second or third quarter of 2024 and to commence a pivotal clinical trial for PrimeC in ALS treatment by the end of the
year. Additionally, in November 2023, we concluded a successful Type D meeting with the FDA regarding CMC development plans for the expected
Phase 3 pivotal study and subsequent marketing approval. The FDA endorsed our proposed CMC development plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PrimeC
was previously evaluated in a Phase&nbsp;2a clinical trial, or NST002, in 15 people living with ALS, conducted at the Tel Aviv Sourasky
Medical Center, Israel. The primary endpoint of the NST002 trial, which was safety and tolerability, was met. In this trial, the safety
profile observed was consistent with known safety profiles of ciprofloxacin and celecoxib. Side effects were mild and transient in nature.
There were no new or unexpected safety signals detected during the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>
</DIV>
<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally,
we observed positive clinical signals in comparison to virtual controls, and a serum biomarker analysis showed significant changes following
treatment, indicating biological activity of the drug in comparison to untreated matched ALS patients. All 12 patients who completed
the NST002 trial elected to continue into an extension study with PrimeC, that was conducted as an Investigator Initiated Study. To date,
the Company is still supporting the drug supply for a few of the participants in this study, which is over 40&nbsp;months since NST002
was initiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
completed three additional studies in 2022 as part of our drug development program to further support our future regulatory submissions.
In April&nbsp;2022, we initiated a pharmacokinetic, or PK, study of PrimeC.&nbsp;The PK open-label, randomized, single-dose, three-treatment,
three-period crossover study evaluated the effect of food on the bioavailability of PrimeC as compared to the bioavailability of co-administered
ciprofloxacin tablets and celecoxib capsules in adult subjects in the U.S.&nbsp;under an FDA cleared IND protocol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
August&nbsp;2022, we completed enrollment and dosing of all subjects in a multi-dose PK study, or NCT05436678. On September&nbsp;28,
2022, we released the results of the NCT05436678 study. Based on results, we believe the PK profile of PrimeC supports the formulation&rsquo;s
extended-release properties, as the concentrations of the active components have been synchronized, aiming to potentially maximize the
synergism between the two compounds. In June&nbsp;2022, we reported the successful completion of the &ldquo;in-life&rdquo; phase of its
90-day GLP toxicology study. In this study, the components of PrimeC, celecoxib and ciprofloxacin, were administered to rodents at doses
4x the maximal clinical dose. All animals appeared normal, with no significant findings observed. The Company intends to present the
data from these studies to the FDA as part of PrimeC&rsquo;s drug development plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
believe we have a strong patent estate, including patents on method of use, combination, and formulation. We secured U.S.&nbsp;Patent
10,980,780 relating to methods for treatment of ALS using ciprofloxacin and celecoxib, the components of PrimeC, which expires in 2038.
This patent also been issued in the European Patent Office, Canada, Australia, Israel and Japan. We also expect to take advantage of
orphan drug exclusivity for PrimeC, if approved, for seven&nbsp;years in the United&nbsp;States and ten&nbsp;years in the European Union.
In addition, U.S.&nbsp;patent application 16/623,467, which relates to methods of treatment of neurodegenerative disease using combinations
of ciprofloxacin and celecoxib, is currently pending. This patent application is expected to expire on June&nbsp;20, 2038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
organization is built around a management team with extensive experience in the pharmaceutical industry, with a particular focus on ALS
research and clinical trials. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory
approval and commercialization of our product candidates. Furthermore, we maintain steadfast and extensive communication and collaboration
with patient advocacy groups and associations, underscoring the importance of patient perspectives in advancing therapeutic strategies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal and commercial
name is NeuroSense Therapeutics Ltd. We were incorporated on February 13, 2017 and were registered as a private company limited by shares
under the laws of the State of Israel. We completed our initial public offering on Nasdaq in December 2021. Our Ordinary Shares and publicly-listed
warrants to purchase Ordinary Shares are traded on Nasdaq under the symbol &ldquo;NRSN&rdquo; and &ldquo;NRSNW,&rdquo; respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 11 HaMenofim Street, Building B, Herzliya, 4672562 Israel, and our telephone number is +972-9-7996183. Our website address
is www.neurosense-tx.com. The information on our website does not constitute a part of this prospectus. Our agent for service of process
in the United States is Cogency Global Inc., c/o The Corporation Trust Company, located at 1180 Avenue of the Americas, Suite 210, New
York, New York 10036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>
<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_004"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issuer</I></FONT></TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroSense
    Therapeutics Ltd.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ordinary Shares to be
    offered by us</I></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,732,000 Ordinary Shares</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Per Ordinary Share offering
    price:</I></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.50 per Ordinary Share</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ordinary Shares to be outstanding<BR>
    immediately following this offering</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,582,042 Ordinary Shares,
    assuming the full exercise of the Pre-Funded Warrants sold hereunder and no exercise of any unregistered warrants to be issued in
    the private placement concurrently with this offering.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pre-Funded Warrants</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also offering Pre-Funded
    Warrants to purchase up to 1,248,000 Ordinary Shares to the purchaser, whose purchase of additional Ordinary Shares in this offering
    would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than
    9.99% of our outstanding share capital immediately following the consummation of this offering and assuming the exercise of such
    warrants. The purchase price of each Pre-Funded Warrant is equal to $1.4999, which is equal to the purchase price of each Ordinary
    Share minus $0.0001, the exercise price of each Pre-Funded Warrant. Each Pre-Funded Warrant is immediately exercisable and may be
    exercised at any time until it has been exercised in full. This offering also relates to the Ordinary Shares issuable upon exercise
    of any Pre-Funded Warrants sold in this offering.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Reasonable Best Efforts</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to issue
    and sell the securities offered hereby to the purchaser through the Placement Agent, and the Placement Agent has agreed to offer
    and sell such securities on a &ldquo;reasonable best efforts&rdquo; basis. The Placement Agent is not required to buy or sell any
    specific number or dollar amount of the securities offered hereby, but will use its reasonable best efforts to sell such securities.
    See &ldquo;Plan of Distribution&rdquo; on page S-15 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Use of Proceeds</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently intend to
    use the net proceeds from the sale of securities for working capital and general corporate purposes. See &ldquo;Use of Proceeds&rdquo;
    on page S-8 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risk Factors</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our securities
    involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-5 of this prospectus supplement and in the
    documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the risks
    you should carefully consider before deciding to invest in our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nasdaq Capital Market Symbol</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Ordinary Shares and
    publicly-listed warrants, each warrant exercisable for one Ordinary Share, are traded on Nasdaq under the symbols &ldquo;NRSN&rdquo;
    and &ldquo;NRSNW,&rdquo; respectively. We do not intend to apply for a listing of the Pre-Funded Warrants or the Ordinary Warrants
    on any national securities exchange or other nationally recognized trading system.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>
</DIV>
<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Concurrent Private Placement</I></FONT></TD>
    <TD STYLE="text-align: justify; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In a concurrent private
    placement, we are also selling to the purchaser of Ordinary Shares and Pre-Funded Warrants in this offering, Ordinary Warrants to
    purchase 2,980,000 Ordinary Shares. The Ordinary Warrants will be exercisable immediately upon issuance at an exercise price of $1.50
    per Ordinary Share and will expire on the fifth anniversary of the original issuance date. The Ordinary Warrants and the Ordinary
    Shares issuable upon the exercise of the Ordinary Warrants, are not being offered pursuant to this prospectus supplement and the
    accompanying prospectus and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and
    Rule 506(b) promulgated thereunder. See the section titled &ldquo;Private Placement Transaction.&rdquo; Pursuant to the securities
    purchase agreement, dated April 10, 2024, by and among the Company and the investor signatory thereto, we will use commercially reasonable
    efforts to cause a registration statement on Form F-1 providing for the resale by holders of&nbsp;&nbsp;Ordinary Shares issuable
    upon the exercise of the Ordinary Warrants, to become effective within 60 days, or within 90 days of the filing of the registration
    statement in the event of a full review by the SEC, and to keep such registration statement effective as provided in the securities
    purchase agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise stated,
all information in this prospectus supplement, is based on 15,602,042 Ordinary Shares outstanding as of April 10, 2024, and does not
include the following as of that date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,069,128 ordinary
                                            shares issuable upon the exercise of options outstanding, at a weighted average exercise
                                            price of $2.30 under our 2018 Employee Share Option Plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">94,000 ordinary
                                            shares issuable upon the vesting of restricted share units outstanding, some of which are
                                            under our 2018 Share Incentive Plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">233,543 ordinary
                                            shares reserved for issuance and available for future grant under our 2018 Share Incentive
                                            Plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">3,000,000 ordinary
                                            shares underlying warrants with an exercise price of $1.50 per share issued in connection
                                            with our registered direct offering in June 2023; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,755,000 ordinary
                                            shares underlying the warrants issued in connection with our initial public offering in December
                                            2021.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise indicated,
all information in this prospectus supplement assumes no exercise of any Pre-Funded Warrants or the Ordinary Warrants issued in the concurrent
private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>
<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our securities involves significant
risks. Before making an investment decision, you should carefully consider the risks described below and under the section titled &ldquo;Item
3. Key Information&mdash;D. Risk Factors&rdquo; in our Annual Report on Form 20-F for the year ended December 31, 2023, as well as the
information included or incorporated by reference in this prospectus supplement and the accompanying prospectus, together with all of
the other information appearing in this prospectus supplement or the accompanying prospectus or incorporated by reference herein or therein,
including in light of your particular investment objectives and financial circumstances. The risks so described are not the only risks
we face. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations and
become material. Our business, financial condition and results of operations could be materially adversely affected by any of these risks.
The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. The discussion
of risks includes or refers to forward-looking statements; you should read the explanation of the qualifications and limitations on such
forward-looking statements discussed elsewhere in this prospectus supplement under the caption &ldquo;Cautionary Statement Regarding
Forward-Looking Statements&rdquo; above.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors in this offering will incur immediate
dilution from the public offering price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the price per share
of our Ordinary Shares being offered is substantially higher than the net tangible book value per share of our Ordinary Shares, you will
suffer immediate and substantial dilution in the net tangible book value of the Ordinary Shares you purchase in this offering. As of
December 31, 2023, our net tangible book value was approximately $(1.9) million, or $(0.12) per Ordinary Share. Based on the offering
price of $1.50 per Ordinary Share and $1.4999 per Pre-Funded Warrant, and our net tangible book value as of December 31, 2023, if you
purchase securities in this offering, you will suffer immediate and substantial dilution of $1.35 per share with respect to the net tangible
book value of our Ordinary Shares. See &ldquo;<I>Dilution</I>&rdquo; for a more detailed discussion of the dilution you will incur in
this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience future dilution as a
result of future equity offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to raise additional
capital, we expect in the future offer additional Ordinary Shares or other securities convertible into or exchangeable for our Ordinary
Shares. We cannot assure you that we will be able to sell Ordinary Shares or other securities in any other offering at a price per share
that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing Ordinary Shares or
other securities in the future could have rights superior to existing shareholders. The price per Ordinary Share at which we sell additional
Ordinary Shares or other securities convertible into or exchangeable for our Ordinary Shares in future transactions may be higher or
lower than the price per Ordinary Share in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Since we have broad discretion in how we
use the proceeds from this offering, we may use the proceeds in ways with which you disagree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend to use
the net proceeds of this offering for working capital and general corporate purposes. Accordingly, our management will have significant
flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use
of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are
being used in ways with which you would agree. It is possible that the net proceeds will be invested in a way that does not yield us
a favorable, or any, return. The failure of our management to use the net proceeds effectively could have a material adverse effect on
our business, financial condition, operating results and cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of the Ordinary Shares may be
volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of the Ordinary
Shares has fluctuated in the past. Consequently, the current market price of the Ordinary Shares may not be indicative of future market
prices, and we may be unable to sustain or increase the value of your investment in the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>This offering is being conducted on a &ldquo;reasonable best
efforts&rdquo; basis.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Placement Agent is offering
the securities on a &ldquo;reasonable best efforts&rdquo; basis, and the Placement Agent is under no obligation to purchase any securities
for its own account. The Placement Agent is not required to sell any specific number or dollar amount of securities in this offering
but will use its reasonable best efforts to sell the securities offered in this prospectus supplement. As a &ldquo;reasonable best efforts&rdquo;
offering, there can be no assurance that the offering contemplated hereby will ultimately be consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to apply for any listing
of the Pre-Funded Warrants on any exchange or nationally recognized trading system, and we do not expect a market to develop for the
Pre-Funded Warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to apply
for any listing of the Pre-Funded Warrants on Nasdaq or any other securities exchange or nationally recognized trading system, and we
do not expect a market to develop for the Pre-Funded Warrants. Without an active market, the liquidity of the Pre-Funded Warrants will
be limited. Further, the existence of the Pre-Funded Warrants may act to reduce both the trading volume and the trading price of our
Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Except as otherwise provided in the Pre-Funded
Warrants, holders of Pre-Funded Warrants purchased in this offering will have no rights as shareholders of Ordinary Shares until such
holders exercise their Pre-Funded Warrants and acquire our Ordinary Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Pre-Funded Warrants offered
in this offering do not confer any rights of Ordinary Share ownership on their holders, such as voting rights or the right to receive
dividends, but rather merely represent the right to acquire our Ordinary Shares at a fixed price. A holder of a Pre-Funded Warrant may
exercise the right to acquire an Ordinary Share and pay a nominal exercise price of $0.0001 at any time. Upon exercise of the Pre-Funded
Warrants, the holders thereof will be entitled to exercise the rights of a holder of our Ordinary Shares only as to matters for which
the record date occurs after the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not receive any additional funds
upon the exercise of the Pre-Funded Warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Pre-Funded Warrant may
be exercised by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but instead would
receive upon such exercise the net number of our Ordinary Shares determined according to the formula set forth in the Pre-Funded Warrant.
Accordingly, we may not receive any additional funds upon the exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We conduct some
of our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza
Strip and Israel&rsquo;s war against them, may affect our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
corporate headquarters is located in Herzliya, Israel. Because we are incorporated under the laws of the State of Israel, and most of
our officers and fourteen out of sixteen of our employees are residents of Israel, our business and operations are directly affected
by economic, political, geopolitical and military conditions in Israel. Since the establishment of the State of Israel in 1948, a number
of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in the region. These
conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which
have negatively affected business conditions in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
October 2023, Hamas terrorists infiltrated Israel&rsquo;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&rsquo;s
border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries,
and Hamas additionally kidnapped many Israeli civilians and soldiers.&nbsp;Following the attack, Israel&rsquo;s security cabinet declared
war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror
attacks. In parallel, border clashes between Israel and the Hezbollah terrorist group on Israel&rsquo;s northern border with Lebanon
intensified and may escalate into a greater regional conflict.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
addition, since the commencement of these events, there have been continued hostilities along Israel&rsquo;s northern border with Lebanon
(with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen). It is possible that hostilities with
Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West
Bank as well as other hostile countries, such as Iran, will join the hostilities. In addition, Iran has threatened to attack Israel and
is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region,
such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. These situations
may potentially escalate in the future to more violent events which may affect Israel and us. Additionally, Yemeni rebel group, the Houthis,
launched series of attacks on global shipping routes in the Red Sea, causing disruptions of supply chain. These geopolitical developments
may adversely affect our ability to continue carrying out various administrative, research, operational and commercial functions and
activities both in Israel and globally.&nbsp;Furthermore, as a result of the war, the international rating agency, Moody&rsquo;s, has
cut Israel&rsquo;s credit rating from A1 to A2 and has also lowered Israel&rsquo;s outlook from stable to negative, stating that it sees
a possible further downgrade in the future. Lowered credit rating of Israel could materially impact&nbsp;our ability to raise capital
and ability to secure loans, if needed, in each case on reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any
hostilities, armed conflicts, terrorist activities involving Israel or the interruption or curtailment of trade between Israel and its
trading partners, or any political instability in the region could directly or indirectly adversely affect business conditions and our
results of operations and could make it more difficult for us to raise capital and could adversely affect the market price of our ordinary
share. An escalation of tensions or violence might result in a significant downturn in the economic or financial condition of Israel,
which could have a material adverse effect on our operations in Israel and our business. Parties with whom we do business have sometimes
declined to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary
in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties
with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under
those agreements pursuant to force majeure provisions in such agreements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
Israel Defense Force, or IDF, the national military of Israel, is a conscripted military service, subject to certain exceptions. Since
October 7, 2023, the IDF has called up several hundred thousand of its reserve forces to serve. Fourteen out of our current 16 employees
are resident in Israel. Three of our five executive officers and four out of 11 other employees who we believe are performing critical
functions reside in Israel. Two of our non-management employees in Israel who do not perform critical functions have been called up,
and additional employees may be called, for service in the current or future wars or other armed conflicts with Hamas, and such persons
may be absent for an extended period of time. As a result, our operations in Israel may be disrupted by such absences, which disruption
may materially and adversely affect our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since
the war broke out on October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced
disruptions to our clinical studies. As such, our clinical and business development activities remain on track. However, the intensity
and duration of Israel&rsquo;s current war against Hamas is difficult to predict at this stage, as are such war&rsquo;s economic implications
on our business and operations and on Israel&rsquo;s economy in general. if the war extends for a long period of time or expands to other
fronts, such as Lebanon, Syria and the West Bank, our operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
of our </FONT>clinical and pre-clinical&nbsp;research and development is&nbsp;currently&nbsp;being conducted outside of Israel,&nbsp;other
than our 12-month open&nbsp;label-extension, or OLE, study of the PARADIGM trial,&nbsp;partially conducted in Tel&nbsp;Aviv,&nbsp;and
a&nbsp;planned&nbsp;Phase 2 trial&nbsp;with PrimeC&nbsp;for&nbsp;AD that we plan to conduct in Haifa, Israel. The OLE has not been affected
by the war, although the quality of the study may be adversely affected if as a result of the war patients are unable to visit the study
center or the study coordinator is not able to conduct home visits and monitor the&nbsp;patients. In addition, in the event of a significant
escalation of hostilities in northern Israel, there may be a delay in the&nbsp;planned&nbsp;AD trial.&nbsp;We do not believe the planned
AD trial will be materially affected by the war and do not anticipate that any such delay as a result of the war would have a material
impact on us. We may also elect to set up a site in Israel for a Phase 3 pivotal ALS trial of PrimeC, but this would be in addition to
numerous other sites in Europe and the United States, and as a result we do not expect the timeline or quality of this trial to be adversely
affected by the war. Our manufacturing is conducted in India. We do not currently anticipate any disruption to the supply chain relevant
to our ongoing clinical trials and believe there are alternative sources of supply from whom we could obtain the necessary finished drug
product to conduct our clinical trials. In addition, we believe we have sufficient finished product in inventory to continue our ongoing
clinical trials for at least the next few months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle
East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by
terrorist attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if maintained, will
be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect
on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally,
political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior
to October 2023, the Israeli government pursued extensive changes to Israel&rsquo;s judicial system, which sparked extensive political
debate and unrest. To date, these initiatives have been substantially put on hold. Actual or perceived political instability in Israel
or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and,
in turn, our business, financial condition, results of operations and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that the net
proceeds from this offering will be approximately $4.3 million, after deducting the Placement Agent fee and estimated offering expenses
payable by us and excluding the proceeds, if any, from the subsequent exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend to use
the net proceeds from the sale of securities for working capital and general corporate purposes. The timing and amount of our actual
expenditures will be based on many factors, and we cannot specify with certainty all of the particular uses of the net proceeds from
this offering. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering.
We have no current commitments or binding agreements with respect to any material acquisition of or investment in any technologies, products
or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending our use of the net
proceeds from this offering, we may invest the net proceeds of this offering in a variety of capital preservation investments, including
but not limited to short-term, investment grade, interest bearing instruments and U.S. government securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares, and we anticipate that, for the foreseeable future, we will retain any future earnings
to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends for
at least the next several years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The distribution of dividends
may also be limited by the Israeli Companies Law, 5759-1999, or the Companies Law, which permits the distribution of dividends only out
of retained earnings or earnings derived over the two most recent fiscal years, whichever is higher, provided that there is no reasonable
concern that payment of a dividend will prevent a company from satisfying its existing and foreseeable obligations as they become due.
As of December 31, 2023, we did not have distributable earnings pursuant to the Companies Law. Dividend distributions may be determined
by our board of directors, as our amended and restated articles of association do not provide that such distributions require shareholder
approval.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_008"></A>DESCRIPTION
OF THE SECURITIES WE ARE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering our Ordinary Shares and Pre-Funded Warrants. For a description of the rights associated with our Ordinary Shares, see &ldquo;Description
of Ordinary Shares&rdquo; in the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Funded
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the Pre-Funded Warrants that are being offered hereby is not complete and is subject
to, and qualified in its entirety by, the provisions of the Pre-Funded Warrant, the form of which will be filed as an exhibit to our
Report on Form 6-K. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete
description of the terms and conditions of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
warrants will be issued in certificated form only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Duration
and exercise price</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Pre-Funded Warrant offered hereby will have an exercise price per Ordinary Share equal to $0.0001. The Pre-Funded Warrants are exercisable
immediately upon issuance, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The exercise
price and number of Ordinary Shares issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock
splits, reorganizations or similar events affecting our Ordinary Shares and the exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercisability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of Ordinary Shares purchased upon such exercise (except in the case of a cashless
exercise as discussed below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder (together with its affiliates) may not exercise any portion of such holder&rsquo;s Pre-Funded Warrant to the extent that the holder
would beneficially own more than 9.99% of the outstanding Ordinary Shares immediately following the consummation of this offering and
assuming the exercise of such warrant, except that upon at least 61 days&rsquo; written prior notice from the holder to us, the holder
may increase or decrease the amount of ownership of Ordinary Shares after exercising the holder&rsquo;s Pre-Funded Warrants up to 9.99%
of the number of Ordinary Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of the Pre-Funded Warrants. No fractional Ordinary Shares will be issued in connection with the exercise
of a Pre-Funded Warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount
multiplied by the exercise price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cashless
exercise</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of the Pre-Funded Warrants will have the right to exercise such warrants on a &ldquo;cashless&rdquo; basis if there is no effective
registration statement registering the issuance of the Ordinary Shares issuable upon the exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fundamental
transactions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any fundamental transaction, as described in the Pre-Funded Warrants and generally including any merger with or into another
entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our Ordinary Shares, then
upon any subsequent exercise of a Pre-Funded Warrant, the holder will have the right to receive as alternative consideration, for each
Ordinary Share that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction,
the number of Ordinary Shares of the successor or acquiring corporation or of our company, if it is the surviving corporation, and any
additional consideration receivable upon or as a result of such transaction by a holder of the number of Ordinary Shares for which the
Pre-Funded Warrant is exercisable immediately prior to such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transferability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned without our consent. The ownership
of the Pre-Funded Warrants and any transfers of the Pre-Funded Warrants will be registered in a warrant register initially maintained
by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
listing</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established trading market for the Pre-Funded Warrants. We do not intend to list the Pre-Funded Warrants on the Nasdaq, any other
national securities exchange or any other nationally recognized trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
as a stockholder</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the Pre-Funded Warrants or by virtue of such holder&rsquo;s ownership of Ordinary Shares, the holders of the
Pre-Funded Warrants do not have the rights or privileges of holders of our Ordinary Shares, including any voting rights, until such Pre-Funded
Warrant holders exercise their Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_009"></A>PRIVATE
PLACEMENT TRANSACTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, we are selling to the purchaser of our Ordinary Shares and Pre-Funded Warrants in this offering, Ordinary
Warrants to purchase 2,980,000 Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ordinary Warrants and the Ordinary Shares issuable upon the exercise of the Ordinary Warrants are not being registered under the Securities
Act, are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the
exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. Accordingly, the purchaser of
the Ordinary Warrants may only sell Ordinary Shares issued upon exercise of the Ordinary Warrants being sold to them in the concurrent
private placement pursuant to an effective registration statement under the Securities Act covering the resale of those shares, an exemption
under Rule 144 under the Securities Act or another applicable exemption under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the Ordinary Warrants that are being offered hereby is not complete and is subject
to, and qualified in its entirety by, the provisions of the Ordinary Warrants, the form of which will be filed as an exhibit to our Report
on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Ordinary Warrant will be exercisable commencing on the date of issuance at an exercise price of $1.50 per Ordinary Share, subject to
adjustment, and will remain exercisable until the fifth anniversary of the original issuance date, but not thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holder of a warrant may exercise its warrant by delivering an appropriately competed and signed exercise notice in the form attached
to the warrant. Payment of the exercise price for the number of shares for which a warrant is being exercised is required to be delivered
within two trading days after exercise of such warrant. A holder of the Ordinary Warrants will have the right to exercise such warrants
on a &ldquo;cashless&rdquo; basis if there is no effective registration statement registering the resale of the Ordinary Shares issuable
upon the exercise of the Ordinary Warrants. Subject to limited exceptions, a holder of the Ordinary Warrants will not have the right
to exercise any portion of such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the
number of our Ordinary Shares outstanding immediately after the issuance of such warrants and assuming the exercise of such warrants.
Any increase in the beneficial ownership limitation shall not be effective until 61 days following notice of such change to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a fundamental transaction
occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every right and power that we may exercise
and will assume all of our obligations under the warrants with the same effect as if such successor entity had been named in the warrant
itself. If holders of our Ordinary Shares are given a choice as to the securities, cash or property to be received in a fundamental transaction,
then the holder shall be given the same choice as to the consideration it receives upon any exercise of the warrant following such fundamental
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In certain circumstances,
the holder will have the right to receive the Black Scholes Value of the warrant calculated pursuant to a formula set forth in the warrants,
payable either in cash or in the same type or form of consideration that is being offered and being paid to the holders of our Ordinary
Shares as described in the warrants.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the securities purchase agreement, as soon as practicable (and in any event, no later than 30 days after the signing of the securities
purchase agreement), the Company is required to file a registration statement with the SEC covering the resale of the Ordinary Shares
issuable upon the exercise of the Ordinary Warrants, and to use commercially reasonable efforts to have the registration statement declared
effective within 60 days or within 90 days of the filing of the registration statement in the event of a full review by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the Ordinary Warrants or by virtue of such holder&rsquo;s ownership of our Ordinary Shares, the holders of such
warrants do not have the rights or privileges of holders of our Ordinary Shares, including any voting rights, until they exercise such
warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the Ordinary Warrants, and we do not expect a market to develop. In addition, we do not intend
to list the Ordinary Warrants on the Nasdaq, any other national securities exchange or any other nationally recognized trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_010"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our total liabilities and shareholders&rsquo; equity as of December 31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an as adjusted basis to give effect to the issuance and sale in this offering of 1,732,000 Ordinary Shares at the purchase price
    of $1.50 per Ordinary Share and the proceeds received from the sale of 1,248,000 Pre-Funded Warrants at the purchase price of $1.4999
    per Pre-Funded Warrant, after deducting the Placement Agent fee and estimated offering expenses payable by us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table should be read in conjunction with &ldquo;Use of Proceeds,&rdquo; our financial statements and related notes that are
incorporated by reference into this prospectus supplement and the accompanying prospectus and the other financial information included
or incorporated by reference into this prospectus supplement and the accompanying prospectus. Our historical results do not necessarily
indicate our expected results for any future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2023<BR> (in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Adjusted</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,640</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,940</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Short term deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Liability in respect of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,518</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,518</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Ordinary shares,&nbsp;no par value per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,379,042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,359,042</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Share premium and capital reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,066</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,066</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Total shareholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,874</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,426</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,392</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">908</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
not reflect the potential classification of all or a portion of the Pre-Funded Warrants as a liability in respect of warrants.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_011"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our Ordinary Shares in this offering, your ownership interest will be diluted to the extent of the difference between the
public offering price per Ordinary Share and the as adjusted net tangible book value per Ordinary Share immediately after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net tangible book value as of December 31, 2023 was approximately $(1.9) million, or $(.012) per share. Net tangible book value per Ordinary
Share is determined by dividing our total tangible assets (including our right-of-use lease assets), less total liabilities, by the number
of Ordinary Shares outstanding as of December 31, 2023. Dilution with respect to net tangible book value per Ordinary Share represents
the difference between the amount per Ordinary Share paid by the purchaser of Ordinary Shares in this offering and the net tangible book
value per Ordinary Share immediately after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the issuance and sale of 1,732,000 Ordinary Shares at the purchase price of $1.50 per Ordinary Share and the proceeds
received from the sale of 1,248,000 Pre-Funded Warrants in this offering at the purchase price of $1.4999 per Pre-Funded Warrant, after
deducting the Placement Agent fee and estimated offering expenses payable by us, our as adjusted net tangible book value as of December
31, 2023 would have been approximately $2.43 million, or $0.13 per Ordinary Share. This amount represents an increase in the net tangible
book value of $0.25 per Ordinary Share to our existing shareholders and an immediate dilution in net tangible book value of $1.35 per
Ordinary Share to new investors purchasing Ordinary Shares in this offering. The following table illustrates this per Ordinary Share
dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: -9pt; padding-left: 9pt">Public offering price per Ordinary Share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Public offering price per Pre-Funded Warrant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.4999</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Net tangible book value per Ordinary Share as of December 31, 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Net increase in net tangible book value per Ordinary Share attributable to existing shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">As adjusted net tangible book value per Ordinary Share after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Dilution in net tangible book value per Ordinary Share to new investors in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion and table above assume no exercise of Pre-Funded Warrants sold in this offering or the Ordinary Warrants issued in the concurrent
private placement, are based on 15,379,042 Ordinary Shares outstanding as of December 31, 2023, and do not include the following as of
that date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,069,128
Ordinary Shares issuable upon the exercise of options outstanding as of December 31, 2023, at a weighted average exercise price of $2.34
under our 2018 Employee Share Option Plan;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">317,000
Ordinary Shares issuable upon the vesting of restricted share units outstanding, some of which are under our 2018 Share Incentive Plan;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">233,543
Ordinary Shares reserved for issuance and available for future grant under our 2018 Share Incentive Plan;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000
Ordinary Shares underlying warrants with an exercise price of $1.50 per share issued in connection with our registered direct offering
in June 2023; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,755,000
Ordinary Shares underlying the warrants issued in connection with our initial public offering in December 2021.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_012"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./Alliance
Global Partners, which we refer to herein as the Placement Agent, located at 590 Madison Ave 28th Floor, New York, NY 10022, has agreed
to act as our exclusive Placement Agent in connection with this offering subject to the terms and conditions of the placement agency
agreement dated April 10, 2024. The Placement Agent is not purchasing or selling any of the securities offered by this prospectus supplement,
nor is it required to arrange the purchase or sale of any specific number or dollar amount of securities, but it has agreed to use its
reasonable best efforts to arrange for the sale of all of the securities offered hereby. Therefore, we will enter into a securities purchase
agreement directly with the purchaser in connection with this offering and we may not sell the entire amount of securities offered pursuant
to this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will deliver the securities being issued to the purchaser upon receipt of funds for the purchase of the securities offered pursuant to
this prospectus supplement. We expect to deliver the Ordinary Shares and Pre-Funded Warrants being offered pursuant to this prospectus
supplement on or about April 15, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the Placement Agent and specified other persons against specified liabilities, including liabilities under the
Securities Act, and to contribute to payments the Placement Agent may be required to make in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees
and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged A.G.P./Alliance Global Partners as our exclusive Placement Agent in connection with this offering. This offering is being
conducted on a &ldquo;reasonable best efforts&rdquo; basis and the Placement Agent has no obligation to buy any of the securities from
us or to arrange for the purchase or sale of any specific number or dollar amount of securities. We have agreed to pay the Placement
Agent fees set forth in the table below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">PER<BR> ORDINARY<BR> SHARE</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">PER<BR> PRE-FUNDED<BR> WARRANT</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">TOTAL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.4999</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,469,875.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent fees<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.105</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.104993</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312,891.27</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to the Company (before expenses)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.395</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.394907</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,156,983.93</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to pay the Placement Agent a Placement Agent&rsquo;s fees of up to 7.0% of the aggregate gross proceeds raised from the sale of the securities sold pursuant to this offering. The Placement Agent has agreed to credit us 3.5% of the placement agent fee and has also agreed to be paid the placement agent fee in the form of a $50,000 fee in cash and to receive 70,964 of our Ordinary Shares </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also agreed to reimburse
the Placement Agent at closing for legal and other expenses incurred by them in connection with the offering in an amount not to exceed
$25,000. We estimate the total expenses payable by us for this offering, excluding the Placement Agent fees and expenses, will be approximately
$95,000.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements
of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and
Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the Placement
Agent acting as principal. Under these rules and regulations, the Placement Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    not engage in any stabilization activity in connection with our securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted
    under the Exchange Act, until it has completed its participation in the distribution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Ordinary Shares and warrants, each warrant exercisable for one Ordinary Share, are traded on Nasdaq under the symbols &ldquo;NRSN&rdquo;
and &ldquo;NRSNW,&rdquo; respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and officers have entered into lock-up agreements. Under these agreements, these individuals have agreed, subject to specified
exceptions, not to sell or transfer any Ordinary Shares or securities convertible into, or exchangeable or exercisable for, our Ordinary
Shares during a period ending ninety (90) days after the date of this prospectus supplement, without first obtaining the written consent
of the Placement Agent. Specifically, these individuals have agreed, in part, not to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
    offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &ldquo;put equivalent
    position&rdquo; within the meaning of Rule 16a-l(h) under the Exchange Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
    into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
    of our securities, whether any such transaction is to be settled by delivery of our ordinary shares, in cash or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any demand for or exercise any right with respect to the registration of any of our securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicly
    disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge, or other arrangement
    relating to any of our securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
these limitations, these Ordinary Shares may be transferred under limited circumstances, including, without limitation, by gift, will
or intestate succession.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have agreed
that for a period of sixty (60) days following the closing of this offering (i) we will not conduct any issuances of our Ordinary Shares,
subject to customary exceptions, or (ii) file any registration statement or amendment or supplement thereto (other than on Form S-8 or
in connection with the resale of the unregistered warrants issued in the concurrent private placement). In addition, we agreed that we
will not conduct any sales of Ordinary Shares or equivalent securities involving a variable rate transaction for a period of one hundred
and eighty (180) days following the closing of this offering provided that after sixty (60) days we shall be permitted to make sales pursuant
to an at-the-market facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent does not intend to confirm sales of the securities offered hereby to any accounts over which it has discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Activities and Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent and its affiliates have provided us and our affiliates in the past and may provide from time to time in the future certain
commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their
business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, the
Placement Agent and its affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves
or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. In particular, the
Placement Agent served as our agent under the Sales Agreement, dated April 14, 2023, providing for an &ldquo;at-the-market&rdquo; offering
and served as our placement agent in a registered direct offering and concurrent private placement that closed in June 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of their various business activities, the Placement Agent and certain of its affiliates may make or hold a broad
array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including
bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve
securities and/or instruments issued by us and our affiliates. If the Placement Agent or its affiliates have a lending relationship with
us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The Placement Agent and
its affiliates may hedge such exposure by entering into transactions that consist of either the purchase of credit default swaps or the
creation of short positions in our securities or the securities of our affiliates, including potentially the Ordinary Shares offered
hereby. Any such short positions could adversely affect future trading prices of the Ordinary Shares offered hereby. The Placement Agent
and certain of its affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish
or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients
that they acquire, long and/or short positions in such securities and instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement in electronic format may be made available on a website maintained by the Placement Agent, and the Placement Agent
may distribute this prospectus supplement electronically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_013"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal matters with respect to Israeli law and with respect to the validity of the offered securities under Israeli law will be passed
upon for us by Goldfarb Gross Seligman &amp; Co. Certain legal matters with respect to U.S. law will be passed upon for us by Greenberg
Traurig, P.A. Certain legal matters will be passed upon for the sales agent by Sullivan &amp; Worcester LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_014"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of NeuroSense Therapeutics Ltd. as of December 31, 2023 and 2022, and for each of the years in the
three-year period ended December 31, 2023, have been incorporated by reference herein in reliance upon the report of Somekh Chaikin,
a member firm of KPMG International, independent registered public accounting firm, incorporated by reference herein, and upon the authority
of said firm as experts in accounting and auditing. The audit report covering the December 31, 2023 consolidated financial statements
contains an explanatory paragraph that states that the Company&rsquo;s recurring losses and its expectation to incur significant additional
losses raise substantial doubt about the entity&rsquo;s ability to continue as a going concern. The consolidated financial statements
do not include any adjustments that might result from the outcome of that uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_015"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of the registration statement on Form F-3 we filed with the SEC under the Securities Act, with respect to the securities
offered by this prospectus. However, as is permitted by the rules and regulations of the SEC, this prospectus, which is part of our registration
statement on Form F-3, omits certain non-material information, exhibits, schedules and undertakings set forth in the registration statement.
For further information about us, and the securities offered by this prospectus, please refer to the registration statement and the exhibits
and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or
incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of
these securities in any state where the offer is not permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the reporting requirements of the Exchange Act that are applicable to a foreign private issuer. In accordance with the
Exchange Act, we file reports, including annual reports on Form 20-F by April 30 of each year. We also furnish to the SEC under cover
of Form 6-K material information required to be made public in Israel, filed with and made public by any stock exchange or distributed
by us to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers, such
as us, that file electronically with the SEC (http://www.sec.gov).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements
to shareholders and our officers, directors and principal shareholders are exempt from the &ldquo;short-swing profits&rdquo; reporting
and liability provisions contained in Section 16 of the Exchange Act and related Exchange Act rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_016"></A>EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth costs and expenses, other than any placement agent fees and expenses, we expect to incur in connection with
the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">- </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing
    expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous
    fees and expenses</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">denotes
estimate</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_017"></A>INFORMATION
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual and special reports and other information with the SEC (File Number 001-41084). These filings contain important information
which does not appear in this prospectus. The SEC allows us to &ldquo;incorporate by reference&rdquo; information into this prospectus,
which means that we can disclose important information to you by referring you to other documents which we have filed or will file with
the SEC. We are incorporating by reference in this prospectus the documents listed below and all amendments or supplements we may file
to such documents, as well as any future filings we may make with the SEC on Form 20-F under the Exchange Act before the time that all
of the securities offered by this prospectus have been sold or de-registered:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on <U><A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390024030439/ea0202964-20f_neuro.htm">Form
    20-F</A></U> for the year ended December 31, 2023, filed on April 4, 2024; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our ordinary shares contained under the heading &ldquo;Item 1. Description of Registrant&rsquo;s Securities to be
    Registered&rdquo; in our registration statement on <U><A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390021060442/ea150948-8a12b_neurosense.htm">Form 8-A</A></U>, as filed with the SEC on November 18, 2021, including any subsequent
    amendment or any report filed for the purpose of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
subsequent Annual Reports filed by us pursuant to the Exchange Act on Form 20-F prior to the termination of this offering shall be deemed
to be incorporated by reference to this prospectus supplement and the accompanying prospectus and to be a part hereof and thereof from
the date of filing of such documents. We may also incorporate any Form 6-K subsequently submitted by us to the SEC prior to the termination
of this offering by identifying in such Forms 6-K that they are being incorporated by reference herein and in the accompanying prospectus,
and any Forms 6-K so identified shall be deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus
and to be a part hereof from the date of submission of such documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements in and portions of this prospectus update and replace information in the above listed documents incorporated by reference.
Likewise, statements in or portions of a future document incorporated by reference in this prospectus may update and replace statements
in and portions of this prospectus or the above listed documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide each person, including any beneficial owner to whom a prospectus is delivered, without charge, upon a written or oral request,
a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which are not specifically
incorporated by reference into such documents. Please direct your written or telephone requests to NeuroSense Therapeutics Ltd., 11 HaMenofim
Street, Building B, Herzliya, 4672562, Israel, Attn: Or Eisenberg, telephone number +972587531153. You may also obtain information about
us by visiting our website at www.neurosense-tx.com. Information contained in our website is not part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$100,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ordinary Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Debt Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Subscription Rights and/or Units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Offered by the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEUROSENSE THERAPEUTICS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may offer and sell to
the public from time to time in one or more series or issuances up to $100,000,000 in the aggregate of ordinary shares, warrants to purchase
ordinary shares and/or debt securities, debt securities (including convertible debt securities), subscription rights and/or units consisting
of two or more of these classes or series of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We refer to the ordinary
shares, warrants, debt securities, subscription rights and units collectively as &ldquo;securities&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Each time we offer to sell
securities pursuant to this prospectus, we will provide a supplement to this prospectus that contains specific information about the
offering and the specific terms of the securities offered. We may also authorize one or more free writing prospectuses to be provided
to you in connection with these offerings. This prospectus may not be used to consummate a sale of securities by us unless accompanied
by the applicable prospectus supplement. You should carefully read this prospectus, the applicable prospectus supplement and any applicable
free writing prospectuses, as well as any documents incorporated by reference, before you invest in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We
may, from time to time, offer to sell the securities, through public or private transactions, directly or through underwriters, agents
or dealers, on or off the Nasdaq Capital Market, as applicable, at prevailing market prices or at privately negotiated prices. If any
underwriters, agents or dealers are involved in the sale of any of these securities, the applicable prospectus supplement will set forth
the names of the underwriter, agent or dealer and any applicable fees, commissions or discounts. For additional information on the methods
of sale, you should refer to the section titled &ldquo;Plan of Distribution&rdquo; in this prospectus and in the applicable prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our
ordinary shares and warrants, each warrant exercisable for one ordinary share, are traded on the Nasdaq Capital Market under the symbols
&ldquo;NRSN&rdquo; and &ldquo;NRSNW,&rdquo; respectively. The last reported sale price for our ordinary shares on January 18, 2023 as
quoted on the Nasdaq Capital Market was $1.26 per share, and the last reported sale price for our warrants on January 18, 2023 as quoted
on the Nasdaq Capital Market was $0.235 per warrant.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of January 18, 2023, the aggregate market value worldwide of our outstanding voting and non-voting common equity held by non-affiliates
was approximately $10.64 million, based on 11,781,963 ordinary shares outstanding, of which 8,444,108 ordinary shares were held by non-affiliates,
and a per ordinary share price of $1.26 based on the closing sale price of our ordinary shares on the Nasdaq Capital Market on January
18, 2023</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">. Pursuant to General Instruction I.B.5 of Form F-3, in
no event will we sell, pursuant to the registration statement of which this prospectus forms a part, securities with a value exceeding
one-third of the aggregate market value of our outstanding ordinary shares held by non-affiliates in any 12-month period, so long as the
aggregate market value of our ordinary shares held by non-affiliates is less than $75.0 million. We have not offered or sold any securities
pursuant to General Instruction I.B.5 on Form F-3 during the prior 12 calendar month period that ends on and includes the date of this
prospectus.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company&rdquo; and a &ldquo;foreign private issuer&rdquo; as defined under the U.S. federal securities laws, and as such, will
be eligible for reduced public company disclosure requirements. See &ldquo;About the Company&mdash;Implications of Being an Emerging
Growth Company and a Foreign Private Issuer&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>Investing in these securities
involves a high degree of risk. Please carefully consider the risks discussed in this prospectus under &ldquo;Risk Factors&rdquo; beginning
on page 4 and the &ldquo;Risk Factors&rdquo; in &ldquo;Item 3. Key Information&mdash;D. Risk Factors&rdquo; of our most recent Annual
Report on Form 20-F incorporated by reference in this prospectus and in any applicable prospectus supplement for a discussion of the
factors you should consider carefully before deciding to purchase these securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of the securities being offered by this prospectus,
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is January 30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; text-align: left; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; unicode-bidi: embed"><B>Page</B></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; width: 90%; text-align: left; unicode-bidi: embed"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: center; unicode-bidi: embed">ii</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THE COMPANY</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">1</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">4</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">5</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">6</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAPITALIZATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">7</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER AND LISTING DETAILS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">8</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">9</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF ORDINARY SHARES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">10</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">11</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">12</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SUBSCRIPTION RIGHTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">18</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">19</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: bottom"><A HREF="#a_014">PLAN OF DISTRIBUTION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">20</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: bottom"><A HREF="#a_015">TAXATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">23</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">24</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">24</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">24</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">25</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENFORCEABILITY OF CIVIL LIABILITIES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">26</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; unicode-bidi: embed"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPENSES ASSOCIATED WITH THE REGISTRATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; unicode-bidi: embed">27</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 27; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">This prospectus is part
of a registration statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), utilizing a &ldquo;shelf&rdquo;
registration process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under this shelf process,
we may sell the securities described in this prospectus in one or more offerings up to a total price to the public of $100,000,000. The
offer and sale of securities under this prospectus may be made from time to time, in one or more offerings, in any manner described under
the section in this prospectus entitled &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">This prospectus provides
you with a general description of the securities we may offer. Each time we sell securities we will provide a prospectus supplement that
will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be
provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing
prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in
the documents we have incorporated by reference herein, and may also contain information about any material federal income tax considerations
relating to the securities covered by the prospectus supplement. You should read both this prospectus, the applicable prospectus supplement
and any related free writing prospectuses we have authorized for use in connection with a specific offering, together with additional
information under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>This prospectus may not
be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have not authorized any
other person to provide you with different or additional information other than that contained in or incorporated by reference into this
prospectus or any applicable prospectus supplement. We do not take any responsibility, and can make no assurance as to the reliability
of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the
offer or sale is not permitted. You should assume that the information appearing in this prospectus, the applicable prospectus supplement
and any free writing prospectus being used in connection with the offering is accurate only as of the date on its respective cover, and
that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate
otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">You should read this entire
prospectus, including the financial statements and related notes and other financial data incorporated by reference in this prospectus,
any applicable prospectus supplement and free writing prospectus, and the documents incorporated herein and therein, before making an
investment decision. This prospectus and the documents incorporated by reference herein contain forward-looking statements that involve
risks and uncertainties. Our actual results may differ significantly from the results discussed in the forward-looking statements. Factors
that might cause or contribute to such differences include those discussed in &ldquo;Risk Factors&rdquo; and &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
or the context otherwise requires, in this prospectus, &ldquo;NeuroSense,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo;
and &ldquo;our&rdquo; refer to NeuroSense Therapeutics Ltd. and its consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_002"></A>ABOUT THE COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We
are a clinical-stage&nbsp;biotechnology company focused on discovering and developing treatments for patients suffering from neurodegenerative
diseases, including Amyotrophic Lateral Sclerosis (&ldquo;ALS&rdquo;), Alzheimer&rsquo;s disease (&ldquo;AD&rdquo;) and Parkinson&rsquo;s
disease (&ldquo;PD&rdquo;). We believe these diseases represent some of the most significant unmet medical needs of our time, with limited
effective therapeutic options available. The burden of these diseases on both patients and society is substantial. For example, the average
annual cost of ALS alone is $180,000 per patient, and its estimated annual burden on the U.S. healthcare system is greater than $1&nbsp;billion.
Due to the complexity of neurodegenerative diseases, our strategy is utilize a combined therapeutic approach to target multiple disease-related
pathways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our
lead therapeutic candidate, PrimeC, is a novel extended-release oral formulation, fixed-dose combination of two FDA-approved&nbsp;drugs,
ciprofloxacin and celecoxib. PrimeC is designed to treat ALS by modulating microRNA synthesis, iron accumulation, and neuroinflammation,
all of which are hallmarks of ALS pathology. The U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) and the European Medicines Agency
(&ldquo;EMA&rdquo;), have granted PrimeC orphan drug designation for the treatment of ALS. We believe PrimeC&rsquo;s multifactorial mechanism
of action has the potential to significantly prolong lifespan and improve ALS patients&rsquo; quality of life, thereby reducing the burden
of this debilitating disease on both patients and healthcare systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In
addition to PrimeC, we have conducted research and development efforts in AD and PD, with a similar strategy of combined products. The
following chart represents our current product development pipeline:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">PrimeC
has been evaluated at the Tel Aviv Sourasky Medical Center, Israel in a Phase 2a clinical trial in 15 people living with ALS (NST002).
The primary endpoint of the NST002 trial, which was safety and tolerability, was met. In this trial, the safety profile observed was
consistent with known safety profiles of ciprofloxacin and celecoxib. Side effects were mild and transient in nature. There were no new
or unexpected safety signals detected during the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.65pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In
addition, NST002 efficacy data demonstrated slower decline per month in both ALS Functional Rating Scale (&ldquo;ALSFRS-R&rdquo;) score
and pulmonary vital capacity endpoint evaluations in ALS patients who were administered with PrimeC compared to matched controls from
the PRO-ACT database (virtual controls). The analysis of key ALS pathology markers in neuron-derived exosomes (&ldquo;NDEs&rdquo;) indicated
that there was a statistically significant reduction in the levels of TDP-43, a key protein in ALS pathology, and PgJ2, representing
neuroinflammation, when compared to baseline measurements over 12 months following PrimeC treatment. Levels of LC3, a marker of autophagy,
which has been shown to be impaired in ALS, were increased from baseline measurements to 12 months. The statistically significant changes
following treatment of PrimeC in the biomarker analysis suggest early evidence of biological activity of the drug, which correlated to
the clinical outcomes observed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.65pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">PrimeC
is currently being evaluated in Paradigm, a Phase 2b randomized, multi-center, multinational, prospective, double-blind, placebo-controlled
study, with an open label extension, to evaluate safety, tolerability, and efficacy of PrimeC in 69 people living with ALS. The study
commenced recruitment of patients in Israel in May 2022 and is currently ongoing. To date, over 50% of the study participants have been
enrolled. With new sites anticipated to be opening in Q1 2023, we expect to report top-line&nbsp;results in the second half of 2023.
On October 14, 2022, we submitted an amendment to our Investigational New Drug Application for Paradigm to the FDA. On December 13, 2022,
the FDA provided a comment that the data submitted do not support the entire study duration. We determined that we will not commence
patient enrollment in the U.S. until we have addressed to satisfaction the FDA&rsquo;s trial duration concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.65pt; background-color: white">&nbsp;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.65pt; background-color: white"></P>

<!-- Field: Page; Sequence: 29; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.65pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We continue to develop our
pipeline. In January 2023, we reported positive final results from our Alzheimer&rsquo;s Biomarker Study, which suggested that a novel
biomarker, TDP-43, may be associated with AD. These findings indicate that NeuroSense&rsquo;s platform technology has the potential to
treat people who suffer from AD. NeuroSense intends to initiate a Phase 2 proof-of-concept study to assess its therapeutic potential in
people who suffer from Alzheimer&rsquo;s disease in H1 2023. TDP-43 has been observed to colocalize with senile plaques and neurofibrillary tangles, suggesting a direct interaction
between TDP-43 and amyloid-&beta; (A&beta;) or tau, which are known to be hallmark biomarkers in AD. TDP-43 has been found in up to 57%
of AD cases and aggregates of TDP-43 have been shown to be cytotoxic both in vitro and in vivo.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our legal and commercial
name is NeuroSense Therapeutics Ltd. We were incorporated on February 13, 2017 and were registered as a private company limited by shares
under the laws of the State of Israel. Our ordinary shares and warrants are traded on the Nasdaq Capital Market under the symbol &ldquo;NRSN&rdquo;
and &ldquo;NRSNW,&rdquo; respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our
principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya, 4672562 Israel, and our telephone number is +972-9-7996183.
Our website address is www.neurosense-tx.com. The information on our website does not constitute a part of this prospectus. Our agent
for service of process in the United States is Cogency Global Inc., c/o The Corporation Trust Company, located at 1180 Avenue of the
Americas, Suite 210, New York, New York 10036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Implications of Being
an Emerging Growth Company and a Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Emerging Growth
Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As
a company with less than $1.235&nbsp;billion in revenue during our last fiscal year, we are an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). As such, we may take advantage of certain
exemptions from various reporting requirements that are applicable to other publicly traded entities that are not emerging growth companies.
These exemptions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the option to present only two years of audited financial
statements and a discussion of only two years of our Operating Financial Review and Prospects in our Annual Report on Form 20-F;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">not being required to have our registered independent public
accounting firm attest to management&rsquo;s assessment of our internal control over financial reporting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">not being required to comply with any requirement that may
be adopted by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;), regarding mandatory audit firm rotation or a supplement
to the auditor&rsquo;s report providing additional information about the audit and the financial statements (i.e., an auditor discussion
and analysis);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">not being required to submit certain executive compensation
matters to stockholder advisory votes, such as &ldquo;say-on-pay,&rdquo; &ldquo;say-on-frequency&rdquo; and &ldquo;say-on-golden&nbsp;parachutes&rdquo;;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">not
being required to disclose certain executive compensation related items such as the correlation between executive compensation and performance
and comparisons of the chief executive officer&rsquo;s compensation to median employee compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As
a result, the information contained in this prospectus, the prospectus supplement and the documents incorporated by reference herein
and therein may be different from the information you receive from other public companies in which you hold shares. We may take advantage
of these provisions for up until we are no longer an emerging growth company. We would cease to be an emerging growth company upon the
earliest to occur of: (i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1.235&nbsp;billion; (ii)&nbsp;the
date on which we have issued more than $1&nbsp;billion in non-convertible&nbsp;debt securities during the previous three years; (iii)&nbsp;the
date on which we are deemed to be a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2&nbsp;under the Exchange Act; or (iv)
the last day of the fiscal year following the fifth anniversary of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Foreign Private
Issuer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We
are also a non-U.S. company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long
as we continue to qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange
Act that are applicable to U.S. domestic public companies, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the rules under the Exchange Act requiring domestic filers
to issue financial statements prepared under U.S. GAAP;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the sections of the Exchange Act regulating the solicitation
of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the sections of the Exchange Act requiring insiders to file
public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period
of time; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the rules under the Exchange Act requiring the filing with
the SEC of quarterly reports on Form 10-Q&nbsp;containing unaudited financial statements and other specified information, and current
reports on Form 8-K&nbsp;upon the occurrence of specified significant events.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
these exemptions, we will file with the SEC, within four months after the end of each fiscal year, or such applicable time as required
by the SEC, an annual report on Form 20-F&nbsp;containing financial statements audited by an independent registered public accounting
firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We
may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private
issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances
applies: (i)&nbsp;the majority of our executive officers or directors are U.S. citizens or residents; (ii)&nbsp;more than 50% of our
assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Both
foreign private issuers and emerging growth companies also are exempt from certain more stringent executive compensation disclosure rules.
Thus, even if we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt
from the more stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private
issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
</DIV>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">An investment in our securities
involves a high degree of risk. Our business, financial condition or results of operations could be adversely affected by any of these
risks. You should carefully consider the risk factors discussed under the caption &ldquo;Item 3: Key Information<B>&mdash;</B>D. Risk
Factors&rdquo; in our Annual Report on Form 20-F for the year ended December 31, 2021, and any updates to those risk factors in our reports
on Form 6-K incorporated by reference herein, together with all of the other information appearing or incorporated by reference in this
prospectus and any applicable prospectus supplement or free writing prospectus, before making your investment decision. The risks and
uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we
currently deem immaterial may also affect our operations. Past financial performance may not be a reliable indicator of future performance,
and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our
business, business prospects, financial condition or results of operations could be seriously harmed. This could cause the trading price
of our ordinary shares to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below
entitled &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Financial Position</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our recurring operating losses have raised
substantial doubt regarding our ability to continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our recurring operating
losses and our expectation to incur additional significant losses raise substantial doubt about our ability to continue as a going concern.
We have no current source of revenue to sustain our present activities and we do not expect to generate revenue until, and unless, the
FDA or other regulatory authorities approve, and we successfully commercialize, our product candidates. Accordingly, our ability to continue
as a going concern will require us to obtain additional financing to fund our operations. The perception that we might be unable to continue
as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the
loss of confidence by investors, suppliers and employees. As a result, for the year ended December 31, 2022, we expect that our financial
statements will include a going concern reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>OFFER STATISTICS AND EXPECTED TIMETABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may sell from time to
time pursuant to this prospectus (as may be detailed in a prospectus supplement) an indeterminate number of ordinary shares, warrants
to purchase ordinary shares and/or debt securities, subscription rights and/or units comprised of any of the foregoing securities as
shall have a maximum aggregate offering price of $100,000,000. The actual price per share or per security of the securities that we will
offer pursuant hereto will depend on a number of factors that may be relevant as of the time of offer. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We make forward-looking
statements in this prospectus and the documents incorporated by reference herein that are subject to risks and uncertainties. These forward-looking
statements include information about possible or assumed future results of our business, financial condition, results of operations,
liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as &ldquo;believe,&rdquo;
&ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;should,&rdquo;
&ldquo;plan,&rdquo; &ldquo;expect,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; or the negative of these terms or other similar
expressions. Forward-looking statements are based on information we have when those statements are made or our management&rsquo;s good
faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance
or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks and uncertainties
include factors relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our limited operating history and history of incurring significant
losses and negative cash flows since our inception, which we anticipate will continue for the foreseeable future;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our dependence on the success of our lead product candidate,
PrimeC, including our obtaining of regulatory approval to market PrimeC in the United States;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our limited experience in conducting clinical trials and reliance
on clinical research organizations and others to conduct them;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to advance our preclinical product candidates
into clinical development and through regulatory approval and commercialization;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the results of our clinical trials, which may fail to adequately
demonstrate the safety and efficacy of our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to achieve the broad degree of physician adoption
and use and market acceptance necessary for commercial success;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our reliance on third parties in marketing, producing or distributing
products and research materials for certain raw materials, compounds and components necessary to produce PrimeC for clinical trials and
to support commercial scale production of PrimeC, if approved;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our receipt of regulatory clarity and approvals for our therapeutic
candidates and the timing of other regulatory filings and approvals;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">estimates of our expenses, revenues, capital requirements
and our needs for additional financing;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our efforts to obtain, protect or enforce our patents and
other intellectual property rights related to our product candidates and technologies; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the impact of the public health, political and security situation
in Israel, the U.S. and other countries in which we may obtain approvals for our products or our business.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The preceding list is not
intended to be an exhaustive list of all of our risks and uncertainties. As a result of these factors, we cannot assure you that the
forward-looking statements in this prospectus, any applicable prospectus supplement and free writing prospectus will prove to be accurate.
Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties
in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person
that we will achieve our objectives and plans in any specified time frame, or at all. In addition, statements that &ldquo;we believe&rdquo;
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available
to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or
review of, all relevant information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">You should review carefully
the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; in this prospectus, any applicable prospectus supplement
and free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus
for a discussion of these and other risks that relate to our business and investing in our ordinary shares. The forward-looking statements
contained in this prospectus, any applicable prospectus supplement and free writing prospectus, and the documents incorporated by reference
herein and therein are expressly qualified in their entirety by this cautionary statement. Except as required by law, we undertake no
obligation to update publicly any forward-looking statements after the date of this prospectus to conform these statements to actual
results or to changes in our expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The table below sets forth
our total capitalization as of September 30, 2022. The financial data in the following table should be read in conjunction with our financial
statements and notes thereto incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<BR>
 September&nbsp;30,<BR>
2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Ordinary shares,&nbsp;no par value per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$</TD>
    <TD STYLE="text-align: right">-</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: justify">Share premium and capital reserve</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">25,482</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,636</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,846</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,230</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.95pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.95pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.95pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>OFFER AND LISTING DETAILS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&rsquo;s ordinary
shares and warrants began trading on the Nasdaq Capital Market on December 9, 2021 under the ticker symbol &ldquo;NRSN&rdquo; and &ldquo;NRSNW,&rdquo;
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in an applicable prospectus supplement, we currently intend to use the net proceeds from the sale of securities to advance the clinical
development of our lead product candidate, PrimeC for ALS, for the clinical development and preclinical research and development in support
of potential investigational new drug applications for, CogniC for AD, StabiliC for PD, and for other indications, for future research
and development of new product candidates and for working capital and general corporate purposes. We will retain broad discretion over
the use of the net proceeds from the sale of our securities offered by this prospectus and the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF ORDINARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our authorized share capital
consists of 60,000,000 ordinary shares, no par value per share, of which 11,781,963 shares were issued and outstanding as of September
30, 2022.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All of our outstanding ordinary
shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A description of our ordinary
shares can be found under the heading &ldquo;Description of Registrant&rsquo;s Securities to be Registered&rdquo; in our Registration
Statement on Form 8-A as filed with the SEC on November 18, 2021.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>History of Share Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Since January 1, 2020, our
issued share capital has changed as provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 18, 2020, we
entered into a crowd-funding transaction in which we issued 370,356 ordinary shares to 536 different investors for total net consideration
of $447 thousand (net of $52 thousand issuance cost).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On April 26 2020, we entered
into another crowd-funding transaction in which we issued 47,688 shares to 161 different investors for total net consideration of $61
thousand (net of $8 thousand issuance cost).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In February, May, June and
July 2021, we entered into Simple Agreements for Future Equity (each, a &ldquo;SAFE&rdquo;) with four separate investors for aggregate
proceeds of $800 thousand. Pursuant to the terms of each SAFE, upon consummation of an equity financing, we were required to issue to
each investor the number of ordinary shares equal to the purchase amount divided by the SAFE price, which was defined as the price per
share equal to 80% of the equity financing valuation (to be no less than $25,000 thousand). The SAFE Agreements also provide the investor
the right to automatically receive ordinary shares in the case of a liquidity event, defined as a change of control event or an initial
public offering. In the case of a liquidity event the investors are entitled to the number of ordinary shares equal to the investment
amount divided by the liquidity price. The liquidity price is defined as the price per share equal to the Company&rsquo;s valuation at
the time of the liquidity event, multiplied by 80%, and divided by the Company&rsquo;s capitalization (to be no less than $25,000 thousand).
As part of our initial public offering, the SAFEs were converted at a price per share of $2.892 into 276,672 ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In May and October 2021,
we issued 240,000 and 45,000 ordinary shares, respectively, pursuant to the exercise of options at an exercise price of $0.033 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In August and September
2021, we issued 1,837,500 ordinary shares pursuant to the exercise of warrants at a weighted average price of $0.67 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On November&nbsp;9, 2021,&nbsp;we
implemented a&nbsp;1-for-3 split of&nbsp;our&nbsp;share capital, resulting&nbsp;in an increase of the issued and outstanding ordinary
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On December 13, 2021, we
completed our initial public offering and issued 2,000,000 units, each consisting of one ordinary share and a warrant representing the
right to purchase one ordinary share with an exercise price of $6.00 per share, at an initial public offering price of $6.00 per unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the closing
of our initial public offering, on December 13, 2021, we issued 961,440 ordinary shares pursuant to the exercise of options at a weighted
average exercise price of $0.079 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In March 2022, we issued
645,000 ordinary shares upon exercise of warrants issued in our initial public offering at a price per share of $6.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In December 2022, we issued
72,000 ordinary shares pursuant to vesting of RSUs that were granted to our officers in November 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may issue warrants to
purchase ordinary shares and/or debt securities. Warrants may be issued independently or together with any other securities and may be
attached to, or separate from, such securities. Each series of warrants will be issued under a separate warrant agreement to be entered
into between us and a warrant agent. The warrant agent will act solely as our agent and will not assume any obligation or relationship
of agency for or with holders or beneficial owners of warrants. We may also choose to act as our own warrant agent. The terms of any
warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable
prospectus supplement. The description in the applicable prospectus supplement of the warrants we offer will not necessarily be complete
and will be qualified in its entirety by reference to the applicable warrant agreement, which will be filed with the SEC if we offer
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The applicable prospectus
supplement will describe, among other things, the following terms of any warrants in respect of which this prospectus is being delivered:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
title of such warrants;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
aggregate number of such warrants;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
price or prices at which such warrants will be issued and exercised, either for ordinary shares or for debt securities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
currency or currencies in which the price of such warrants will be payable;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
type and number of securities purchasable upon exercise of such warrants;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
date on which the right to exercise such warrants shall commence and the date on which such right shall expire;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued with
each such security;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
applicable, the date on and after which such warrants and the related securities will be separately transferable;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
with respect to book-entry procedures, if any;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
material Israeli and United States federal income tax consequences;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
anti-dilution or other adjustment provisions of the warrants, if any;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
circumstances that will cause the warrants to be deemed to be automatically exercised or required to be exercised in order not to terminate
by their terms; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
other terms of such warrants, including terms, procedures and limitations relating to the exchange and exercise of such warrants.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of September 30, 2022,
1,755,000 of our warrants, each exercisable for one ordinary share, were outstanding and had an average exercise price of $6.09.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amendments and Supplements to Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We and the warrant agent
may amend or supplement the warrant agreement for a series of warrants without the consent of the holders of the warrants issued thereunder
to effect changes that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests
of the holders of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>DESCRIPTION OF DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may issue debt securities
from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While
the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe
the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any
debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise,
whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series
of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will issue the debt securities
under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust
Indenture Act of 1939, as amended (the &ldquo;Trust Indenture Act&rdquo;). We have filed the form of indenture as an exhibit to the registration
statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt
securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated
by reference from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following summary of
material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the
provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements
and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete
indenture that contains the terms of the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The indenture does not limit
the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may
authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and
sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any negative covenants
or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition
or transactions involving us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may issue the debt securities
issued under the indenture as &ldquo;discount securities,&rdquo; which means they may be sold at a discount below their stated principal
amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &ldquo;original
issue discount&rdquo; (&ldquo;OID&rdquo;), for U.S. federal income tax purposes because of interest payment and other characteristics
or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be
described in more detail in any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will describe in the
applicable prospectus supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
title of the series of debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
limit upon the aggregate principal amount that may be issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
maturity date or dates;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
form of the debt securities of the series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
applicability of any guarantees;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any
subordination;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price
other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the
maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security
or the method by which any such portion shall be determined;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue,
the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option,
redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption
provisions;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous
fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities and the currency
or currency unit in which the debt securities are payable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations
with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of
that series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions,
if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary
for such global security or securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon
which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how
it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&rsquo; option) conversion or exchange
features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable
upon declaration of acceleration of the maturity thereof;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">additions
to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation,
merger or sale covenant;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">additions
to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare
the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">additions
to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">additions
to or changes in the provisions relating to satisfaction and discharge of the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">additions
to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities
issued under the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
interest will be payable in cash or additional debt securities at our or the holders&rsquo; option and the terms and conditions upon
which the election may be made;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts
of the debt securities of the series to any holder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
restrictions on transfer, sale or assignment of the debt securities of the series; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes
in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will set forth in the
applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common
stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange
is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common
stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unless we provide otherwise
in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts
our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as
an entirety. However, upon any such consolidation or merger (in each case, if we are not the survivor of such transaction) or any such
sale, conveyance, transfer or other disposition (other than a subsidiary of ours) the successor or acquiror must assume all of our obligations
under the indenture or the debt securities, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Events of Default under the Indenture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unless we provide otherwise
in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture
with respect to any series of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such
default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance
with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable
whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established
with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the
terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant
specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of
such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders
of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
specified events of bankruptcy, insolvency or reorganization occur.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If an event of default with
respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point
above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by
notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any,
and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with
respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and
payable without any notice or other action on the part of the trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The holders of a majority
in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to
the series and its consequences if we have paid or deposited with the trustee a sum sufficient to pay all matured installments of principal
and interest upon all the debt securities of that series that shall have become due otherwise than by acceleration, except defaults or
events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default
in accordance with the indenture. Any waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Subject to the terms of
the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise
any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities,
unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt
securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
direction so given by the holder is not in conflict with any law or the applicable indenture; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">subject
to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might
be unduly prejudicial to the holders not involved in the proceeding.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A holder of the debt securities
of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other
remedies only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
holder has given written notice to the trustee of a continuing event of default with respect to that series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">such
holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee
in compliance with the request; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding
debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These limitations do not
apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest
on, the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will periodically file
statements with the trustee regarding our compliance with specified covenants in the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We and the trustee may change
an indenture without the consent of any holders with respect to specific matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
comply with the provisions described above under &ldquo;Description of Debt Securities&mdash;Consolidation, Merger or Sale;&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
provide for uncertificated debt securities in addition to or in place of certificated debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit
of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in
any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred
upon us in the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication
and delivery of debt securities, as set forth in the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under
&ldquo;Description of Debt Securities&mdash;General&rdquo; to establish the form of any certifications required to be furnished pursuant
to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, under the indenture,
the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of
at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the
following changes only with the consent of each holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">extending
the fixed maturity of any debt securities of any series;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">reducing
the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption
of any series of any debt securities; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">reducing
the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The indenture provides that
we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations,
including obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">provide
for payment;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">register
the transfer or exchange of debt securities of the series;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">replace
stolen, lost or mutilated debt securities of the series;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">pay
principal of and premium and interest on any debt securities of the series;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">maintain
paying agent agreements;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">recover
excess money held by the trustee;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">compensate
and indemnify the trustee; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">appoint
any successor trustee.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In order to exercise our
rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any
premium, if any, and interest on, the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Form, Exchange and Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will issue the debt securities
of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement,
in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in
temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company
(&ldquo;DTC&rdquo;), or another depositary named by us and identified in the applicable prospectus supplement with respect to that series.
To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry
securities will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the option of the holder,
subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement,
the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any
authorized denomination and of like tenor and aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Subject to the terms of
the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt
securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed
thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any
transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer
or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or
other governmental charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will name in the applicable
prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate
for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or
approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in
each place of payment for the debt securities of each series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If we elect to redeem the
debt securities of any series, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">issue,
register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days
before the day of mailing of a notice of redemption of less than all outstanding debt securities of the same series that may be selected
for redemption and ending at the close of business on the day of the mailing; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">register
the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any
debt securities we are redeeming in part.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Concerning the Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The trustee, other than
during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically
set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a
prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation
to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable
security and indemnity against the costs, expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unless we otherwise indicate
in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to
the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular
record date for the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will pay principal of
and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except
that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail
to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate
the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will
name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular
series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All money we pay to a paying
agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at
the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the
debt security thereafter may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that
the Trust Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>DESCRIPTION OF SUBSCRIPTION RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may issue subscription
rights to purchase our ordinary shares. These subscription rights may be issued independently or together with any other security offered
hereby and may or may not be transferable by the shareholder receiving the subscription rights in such offering. In connection with any
offering of subscription rights, we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to
which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The prospectus supplement
relating to any subscription rights we offer, if any, will, to the extent applicable, include specific terms relating to the offering,
including some or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price, if any, for
    the subscription rights;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise price payable
    for each ordinary share upon the exercise of the subscription rights;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of subscription
    rights to be issued to each shareholder; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and terms of
    the ordinary shares which may be purchased per each subscription right;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which the
    subscription rights are transferable; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other terms of the
    subscription rights, including the terms, procedures and limitations relating to the exchange and exercise of the subscription rights;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the right
    to exercise the subscription rights shall commence, and the date on which the subscription rights shall expire;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which the
    subscription rights may include an over-subscription privilege with respect to unsubscribed securities;&nbsp;and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the material
    terms of any standby underwriting or purchase arrangement which may be entered into by us in connection with the offering of subscription
    rights.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The description in the applicable
prospectus supplement of any subscription rights we offer will not necessarily be complete and will be qualified in its entirety by reference
to the applicable subscription right agreement, which will be filed with the SEC if we offer subscription rights. For more information
on how you can obtain copies of the applicable subscription right agreement if we offer subscription rights, see &ldquo;Where You Can
Find More Information&rdquo; and &ldquo;Incorporation of Information by Reference.&rdquo; We urge you to read the applicable subscription
right agreement and any applicable prospectus supplement in their entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_013"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may issue units comprised
of one or more of the other securities that may be offered under this prospectus, in any combination. Each unit will be issued so that
the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and
obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included
in the unit may not be held or transferred separately at any time, or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The prospectus supplement
relating to any units we offer, if any, will, to the extent applicable, include specific terms relating to the offering, including some
or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
material terms of the units and of the securities comprising the units, including whether and under what circumstances those securities
may be held or transferred separately;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising
the units; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
material provisions of the governing unit agreement that differ from those described above.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The description in the applicable
prospectus supplement of any units we offer will not necessarily be complete and will be qualified in its entirety by reference to the
applicable unit agreement, which will be filed with the SEC if we offer units. For more information on how you can obtain copies of the
applicable unit agreement if we offer units, see &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Information
by Reference&rdquo;. We urge you to read the applicable unit agreement and any applicable prospectus supplement in their entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The securities being offered
by this prospectus and any applicable prospectus supplement may be sold, from time to time, in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
agents;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
or through one or more underwriters on a firm commitment or agency basis;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
put or call option transactions relating to the securities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
broker-dealers;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">directly
to a single purchaser or several purchasers, through a specific bidding or auction process, on a negotiated basis or otherwise;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
any other method permitted pursuant to applicable law; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
a combination of any such methods of sale.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may also sell equity
securities covered by this registration statement in an &ldquo;at-the-market offering&rdquo; as defined in Rule 415 under the Securities
Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">on
or through the facilities of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;), or any other securities exchange or quotation or trading
service on which such securities may be listed, quoted or traded at the time of sale; and/or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">other
than on Nasdaq or such other securities exchanges or quotation or trading services.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Such at the market offerings,
if any, may be conducted by underwriters acting as principal or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the time a particular
offer of the securities covered by this prospectus is made, a revised prospectus or prospectus supplement (and any related free writing
prospectus that we may authorize to be provided to you), if required, will be distributed which will set forth the terms of the offering,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            name or names of any underwriters, dealers, brokers or agents;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            method of distribution;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
public offering price or purchase price of the securities and any discounts, commissions, concessions and other items constituting compensation
from us and any discounts, commissions or concessions allowed or reallowed or paid to dealers;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
options under which underwriters may purchase additional securities from us;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
securities exchange or market on which the securities may be listed; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
group of investors targeted potential investors, if any.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Such prospectus supplement,
and, if necessary, a post-effective amendment to the registration statement of which this prospectus is a part, will be filed with the
SEC to reflect the disclosure of additional information with respect to the distribution of the securities covered by this prospectus.
In order to comply with the securities laws of certain states, if applicable, the securities sold under this prospectus may only be sold
through registered or licensed broker-dealers. In addition, in some states the securities may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from registration or qualification requirements is available and is complied
with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The distribution of securities
may be effected from time to time in one or more transactions, including block transactions and transactions on the Nasdaq Capital Market
or any other organized market where the securities may be traded. The securities may be sold at a fixed price or prices, which may be
changed, or at market prices prevailing at the time of sale, at prices relating to the prevailing market prices or at negotiated prices.
The consideration may be cash or another form negotiated by the parties. Agents, underwriters or broker-dealers may be paid compensation
for offering and selling the securities. That compensation may be in the form of discounts, concessions or commissions to be received
from us or from the purchasers of the securities. Any dealers and agents participating in the distribution of the securities may be deemed
to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts. If any
such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Agents may from time to
time solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement any agent involved
in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated in the prospectus
supplement, any agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the securities covered
by this prospectus may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If underwriters are used
in a sale, securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions,
including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale, or under delayed
delivery contracts or other contractual commitments. Securities may be offered to the public either through underwriting syndicates represented
by one or more managing underwriters or directly by one or more firms acting as underwriters. If an underwriter or underwriters are used
in the sale of securities, an underwriting agreement will be executed with the underwriter or underwriters, as well as any other underwriter
or underwriters, with respect to a particular underwritten offering of securities, and will set forth the terms of the transactions,
including compensation of the underwriters and dealers and the public offering price, if applicable. The prospectus, the applicable prospectus
supplement and any free writing prospectus authorized for use in connection with an offering will be used by the underwriters to resell
the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If a dealer is used in the
sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities
to the public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the
prospectus supplement the name of the dealer and the terms of the transactions. Any public offering price and any discounts or concessions
allowed or re-allowed or paid to dealers may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may directly solicit
offers to purchase the securities and may make sales of securities directly to institutional investors or others. These persons may be
deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities. To the extent required,
the applicable prospectus supplement and any free writing prospectus authorized for use in connection with an offering will describe
the terms of any such sales, including the terms of any bidding or auction process, if used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Agents, underwriters and
dealers may be entitled under agreements which may be entered into with us to indemnification by us against specified liabilities, including
liabilities incurred under the Securities Act, or to contribution by us to payments they may be required to make in respect of such liabilities.
If required, the prospectus supplement will describe the terms and conditions of the indemnification or contribution. Some of the agents,
underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us or our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Any person participating
in the distribution of securities registered under the registration statement that includes this prospectus will be subject to applicable
provisions of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and the applicable SEC rules and regulations,
including, among others, Regulation M, which may limit the timing of purchases and sales of any of our securities by that person. Furthermore,
Regulation M may restrict the ability of any person engaged in the distribution of our securities to engage in market-making activities
with respect to our securities. These restrictions may affect the marketability of our securities and the ability of any person or entity
to engage in market-making activities with respect to our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain persons participating
in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, penalty bids and other transactions
that stabilize, maintain or otherwise affect the price of the offered securities. These activities may maintain the price of the offered
securities at levels above those that might otherwise prevail in the open market, including by entering stabilizing bids, effecting syndicate
covering transactions or imposing penalty bids, each of which is described below.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
stabilizing bid means the placing of any bid, or the effecting of any purchase, for the purpose of pegging, fixing or maintaining the
price of a security.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
syndicate covering transaction means the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase
to reduce a short position created in connection with the offering.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
penalty bid means an arrangement that permits the managing underwriter to reclaim a selling concession from a syndicate member in connection
with the offering when offered securities originally sold by the syndicate member are purchased in syndicate covering transactions.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These transactions may be
effected on an exchange or automated quotation system, if the securities are listed on that exchange or admitted for trading on that
automated quotation system, or in the over-the-counter market or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If so indicated in the applicable
prospectus supplement, we will authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase
offered securities from us at the public offering price set forth in such prospectus supplement pursuant to delayed delivery contracts
providing for payment and delivery on a specified date in the future. Such contracts will be subject only to those conditions set forth
in the prospectus supplement and the prospectus supplement will set forth the commission payable for solicitation of such contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, ordinary shares
may be issued upon conversion of or in exchange for debt securities or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Any underwriters to whom
offered securities are sold for public offering and sale may make a market in such offered securities, but such underwriters will not
be obligated to do so and may discontinue any market making at any time without notice. The offered securities may or may not be listed
on a national securities exchange. No assurance can be given that there will be a market for the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Any securities that qualify
for sale pursuant to Rule 144 or Regulation S under the Securities Act, may be sold under Rule 144 or Regulation S rather than pursuant
to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">To the extent that we make
sales to or through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the terms of a distribution
agreement between us and the underwriters or agents. If we engage in at-the-market sales pursuant to a distribution agreement, we will
sell our ordinary shares to or through one or more underwriters or agents, which may act on an agency basis or on a principal basis.
During the term of any such agreement, we may sell ordinary shares on a daily basis in exchange transactions or otherwise as we agree
with the underwriters or agents. The distribution agreement will provide that any ordinary shares sold will be sold at prices related
to the then prevailing market prices for our ordinary shares. Therefore, exact figures regarding proceeds that will be raised or commissions
to be paid cannot be determined at this time and will be described in a prospectus supplement. Pursuant to the terms of the distribution
agreement, we also may agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase, blocks of our
ordinary shares or warrants. The terms of each such distribution agreement will be set forth in more detail in a prospectus supplement
to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with offerings
made through underwriters or agents, we may enter into agreements with such underwriters or agents pursuant to which we receive our outstanding
securities in consideration for the securities being offered to the public for cash. In connection with these arrangements, the underwriters
or agents may also sell securities covered by this prospectus to hedge their positions in these outstanding securities, including in
short sale transactions. If so, the underwriters or agents may use the securities received from us under these arrangements to close
out any related open borrowings of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may enter into derivative
transactions with third parties or sell securities not covered by this prospectus to third parties in privately negotiated transactions.
If the applicable prospectus supplement indicates, in connection with those derivatives, such third parties (or affiliates of such third
parties) may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, such third parties (or affiliates of such third parties) may use securities pledged by us or borrowed from us or others to settle
those sales or to close out any related open borrowings of shares, and may use securities received from us in settlement of those derivatives
to close out any related open borrowings of shares. The third parties (or affiliates of such third parties) in such sale transactions
will be underwriters and, if not identified in this prospectus, will be identified in the applicable prospectus supplement (or a post-effective
amendment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We may loan or pledge securities
to a financial institution or other third party that in turn may sell the securities using this prospectus. Such financial institution
or third party may transfer its short position to investors in our securities or in connection with a simultaneous offering of other
securities offered by this prospectus and any applicable prospectus supplement or in connection with a simultaneous offering of other
securities offered by this prospectus and any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>TAXATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The material U.S. federal
and Israeli income tax consequences, if any, relating to the purchase, ownership and disposition of our securities offered by this prospectus
will be set forth in the prospectus supplement pertaining to the offering of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_016"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain legal matters with
respect to Israeli law and with respect to the validity of the offered securities under Israeli law will be passed upon for us by Gross
&amp; Co.&nbsp;Certain legal matters with respect to U.S. law will be passed upon for us by Covington &amp; Burling LLP, New York, New
York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The financial statements
of NeuroSense Therapeutics Ltd. as of December 31, 2021 and 2020, and for each of the years in the three-year period ended December 31,
2021, have been incorporated by reference herein in reliance upon the report of Somekh Chaikin, a member firm of KPMG International,
independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting
and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">This prospectus is part
of the registration statement on Form F-3 we filed with the SEC under the Securities Act, with respect to the securities offered by this
prospectus. However, as is permitted by the rules and regulations of the SEC, this prospectus, which is part of our registration statement
on Form F-3, omits certain non-material information, exhibits, schedules and undertakings set forth in the registration statement. For
further information about us, and the securities offered by this prospectus, please refer to the registration statement and the exhibits
and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or
incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of
these securities in any state where the offer is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are subject to the reporting
requirements of the Exchange Act that are applicable to a foreign private issuer. In accordance with the Exchange Act, we file reports,
including annual reports on Form 20-F by April 30 of each year. We also furnish to the SEC under cover of Form 6-K material information
required to be made public in Israel, filed with and made public by any stock exchange or distributed by us to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The SEC maintains an Internet
site that contains reports, proxy and information statements, and other information regarding issuers, such as us, that file electronically
with the SEC (<I>http://www.sec.gov</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders and our
officers, directors and principal shareholders are exempt from the &ldquo;short-swing profits&rdquo; reporting and liability provisions
contained in Section 16 of the Exchange Act and related Exchange Act rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_019"></A>INCORPORATION OF CERTAIN
DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We file annual and special
reports and other information with the SEC (File Number 001-41084). These filings contain important information which does not appear
in this prospectus. The SEC allows us to &ldquo;incorporate by reference&rdquo; information into this prospectus, which means that we
can disclose important information to you by referring you to other documents which we have filed or will file with the SEC. We are incorporating
by reference in this prospectus the documents listed below and all amendments or supplements we may file to such documents, as well as
any future filings we may make with the SEC on Form 20-F under the Exchange Act before the time that all of the securities offered by
this prospectus have been sold or de-registered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390022019888/f20f2021_neurosense.htm">Form 20-F</A>
for the fiscal year ended on December 31, 2021, filed with the SEC on April 14, 2022;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
reports on Form 6-K furnished to the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022030250/ea160817-6k_neurosense.htm">May
31, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022035033/ea162090-6k_neurosense.htm">June 27, 2022</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022036070/ea162301-6k_neurosense.htm">June 30, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022039007/ea162781-6k_neurosense.htm">July
13, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022057171/ea166046-6k_neurosense.htm">September 20, 2022</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022059577/ea166444-6k_neurosense.htm">September 28, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022076708/ea169518-6k_neurosense.htm">December
1, 2022</A> and our report on <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390023003794/ea171503-6ka_neurosense.htm" STYLE="-sec-extract: exhibit">Form
6-K/A</A> furnished to the SEC on January 19, 2023 (with respect to Exhibit 99.1, only the text under the headings &ldquo;Business Update&rdquo;
(first two paragraphs), &ldquo;Financial Summary&rdquo;, &ldquo;Forward-Looking Statements&rdquo; and financial tables); and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
description of our ordinary shares contained under the heading &ldquo;Item 1. Description of Registrant&rsquo;s Securities to be Registered&rdquo;
in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390021060442/ea150948-8a12b_neurosense.htm">Form
8-A</A>, as filed with the SEC on November 18, 2021, including any subsequent amendment or any report filed for the purpose of updating
such description.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, any reports
on Form 6-K submitted to the SEC by the registrant pursuant to the Exchange Act after the date of the initial registration statement
and prior to effectiveness of the registration statement that we specifically identify in such forms as being incorporated by reference
into the registration statement of which this prospectus forms a part and all subsequent annual reports on Form 20-F filed after the
effective date of this registration statement and prior to the termination of this offering, shall be considered to be incorporated into
this prospectus by reference and shall be considered a part of this prospectus from the date of filing or submission of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain statements in and
portions of this prospectus update and replace information in the above listed documents incorporated by reference. Likewise, statements
in or portions of a future document incorporated by reference in this prospectus may update and replace statements in and portions of
this prospectus or the above listed documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will provide each person,
including any beneficial owner to whom a prospectus is delivered, without charge, upon a written or oral request, a copy of any of the
documents incorporated by reference in this prospectus, other than exhibits to such documents which are not specifically incorporated
by reference into such documents. Please direct your written or telephone requests to NeuroSense Therapeutics Ltd., 11 HaMenofim Street,
Building B, Herzliya, 4672562, Israel, Attn: Or Eisenberg, telephone number +972587531153. You may also obtain information about us by
visiting our website at&nbsp;<I>www.neurosense-tx.com</I>. Information contained in our website is not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_020"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this
prospectus, substantially all of whom reside outside the United States, may be difficult to obtain within the United States. Furthermore,
because substantially all of our assets and substantially all of our directors and officers are located outside the United States, any
judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have irrevocably appointed
Cogency Global Inc. as our agent to receive service of process in any action against us in any U.S. federal or state court arising out
of this offering or any purchase or sale of securities in connection with this offering. The address of our agent is 1180 Avenue of the
Americas, Suite 210, New York, New York 10036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have been informed by
our legal counsel in Israel, Gross &amp; Co., that it may be difficult to initiate an action with respect to U.S. securities law in Israel.
Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most
appropriate forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law
and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved
as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed by
Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Subject to certain time limitations
and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions, is non-appealable,
including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or
compensatory judgment in a non-civil matter, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the
substance of the judgment is not contrary to public policy; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
judgment is executory in the state in which it was given.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 20pt">Even if these conditions are
met, an Israeli court will not declare a foreign civil judgment enforceable if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
judgment was obtained by fraud;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli
court;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">at
the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a
court or tribunal in Israel.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If a foreign judgment is
enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency
and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency
is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date
of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli
court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory
rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_021"></A>EXPENSES ASSOCIATED WITH
THE REGISTRATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following is a statement
of expenses in connection with the distribution of the securities registered. All amounts shown are estimates except the SEC registration
fee. The estimates do not include expenses related to offerings of particular securities. Each prospectus supplement describing an offering
of securities will reflect the estimated expenses related to the offering of securities under that prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">11,020</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accountants&rsquo; fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Trustee fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Miscellaneous</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">The calculation of these
                                            fees and expenses is dependent on the number of issuances and amount and types of securities
                                            offered and, accordingly, cannot be estimated at this time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroSense
Therapeutics Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1,732,000
Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Funded
Warrants to Purchase up to 1,248,000 Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole&nbsp;Placement Agent</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>A.G.P.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>April
10, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !7 68# 2(  A$! Q$!_\0
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MS;?$&TG9MX!*6X)!4%1GS/7^'&?FK]*_A<;?5OA1\/ID:&X,GA/1WGD;=M:
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MU^(^B?\ !-/]NKX+ZW=6WPC^)HL?#Z9^R_9=9N=-M[Q#SLO--\RX63!/&)D
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M@;S(?,9BFS9(Z-$3W<H(U))],XZY)SQ?;:%R1&\@RN#\F9"!Y<?0_P"LSPP
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M?A!I>E>$=>7P[\2/ WB2T\8^ [ZY<QP0ZG:@*89DCE4[I %_?[R$VD&-N*\
M^&_Q<_X*27VCZ'\-O$?[/&B^&]=BM[;1Y_C'J^N6LFE!;<8^WO811!6\P+@6
M^[((.)F)-3S16E_P9E7=:?PQ;^[]6OZZ'Z<?#74]5\1_#_P9K'B*QN[#6=0\
M.:!=ZG8WD9BOK?5K=%-P)XB%.^=]Q8L5"J!][=E?QT_X+!^!M8TP_ 'XG^$/
M&WC+POXUU/XK>%_ EK8:?K$D'AB6QU(\6L^D1R11S7,?+-/YJ;SG")7[9:)#
MJ4>E6-OJ=R9]0AM+>WU6Y'[F26X@4%KB+;O5?-?<Y09 #8$C,"S?DS_P4V\
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M?"4-AX%LC8:/K'AW67O[K4(1VU"V0^3P>Y9R>.#V**O8G$0C:]M=?S/T,V
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%*#0__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "C G # 2(  A$! Q$!_\0
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M&G_:F/\ I27)=4P,JP. ,G ^6K.@^'X]"64)</-YB1I\R@8V C]<T ;-%%%
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M "0,_G4DEE/% TSA0@VG.X'(/0C'4<&NVT5H<]Y#O[2OO^?R?_OX:/[2OO\
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MU*>X^PS[6;"_+_".!53^QM3_ .?&?_OFIIRBHZO4<DV]BC15[^QM3_Y\9_\
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MWT'6I/[&U/\ Y\9_^^:Z#PMI4]M/-<W4+1,!L0.,'W-9U*L8P;3+A!N23.H
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M65@L,OWXQDX5O<#@U!5<L>Q-V;?_  F/B;_H/ZC_ .!#4?\ "8^)O^@_J/\
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MR:@B3S)57U-273[IB!T7@4 04444 %%%% !5FV 1'F/88%5JLS_NK=(NYY-
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M[&)1@>E;?_"&^)_^A?U+_P !VH_X0WQ/_P!"_J7_ (#M1S1[AROL8F**V_\
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M?$M_)A@#_P LUY/YG:*[ZU@82[G4@#UKQ'XG:=XC\0^,IGMM%U"6SM4$$#K
MQ5L<L1]2?TK>@DYZ]#.H[1T/,J*V_P#A#?$__0OZE_X#M1_PAOB?_H7]2_\
M =J]'FCW.3E?8Q**V_\ A#?$_P#T+^I?^ [4?\(;XG_Z%_4O_ =J.:/<.5]C
M$HK;_P"$-\3_ /0OZE_X#M1_PAOB?_H7]2_\!VHYH]PY7V,2BMO_ (0WQ/\
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M^$BUG_H)7/\ WV:/^$BUG_H)7/\ WV:SMCC^!ORIM'-+N'UFO_/+[W_F:?\
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MLYUIR;2T5V]W\^P?:)?^>AH^T2_\]#45%=A]D2_:)?\ GH:/M$O_ #T-144
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M6;8W)XXIGDR?W&_*@!E%/\F3^XWY4>3)_<;\J &44_R9/[C?E2B"0D#8?RH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
